var docs;if (!docs) docs =[]; docs["99"]={"9902":"<p><b>Title</b> Dapoxetine / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that the likelihood and/or severity of dapoxetine adverse events may be greater with concurrent use of a strong inhibitor of CYP2D6. This increased risk may be particularly significant at the higher 60 mg dose of dapoxetine, so extra caution and closer monitoring may be warranted with use of such higher dapoxetine doses.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The AUC and maximum serum concentration (Cmax) of dapoxetine were an average of 88% and 50% higher, respectively, with concomitant use of the strong CYP2D6 inhibitor fluoxetine (60 mg twice/day for 7 days) among subjects receiving single doses of dapoxetine (60 mg).<sup>1,2</sup> According to the dapoxetine summary of product characteristics, these changes may be even larger when considering both dapoxetine and its active desmethyldapoxetine metabolite.<br><br>The specific mechanism for this apparent interaction is likely inhibition of the CYP2D6-mediated metabolism of dapoxetine, which is primarily metabolized by CYP3A4 and CYP2D6, leading to increased dapoxetine concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Priligy (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. Priligy (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9903":"<p><b>Title</b> Etizolam / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Etizolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patient closely for evidence of reduced etizolam effectiveness.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The etizolam AUC was an average of 46% lower with concurrent use of the strong CYP3A4 inducer carbamazepine in a study of 11 healthy volunteers who received etizolam with or without concurrent carbamazepine (200 mg/day for 6 days).<sup>1</sup> No changes in etizolam pharmacodynamics were found, although this study was not specifically designed or powered to fully evaluate etizolam's effectiveness.<br><br>The exact clinical significance of this interaction is uncertain. No specific management recommendations are included in the etizolam labeling concerning use of etizolam together with carbamazepine or other strong CYP3A4 inducers,<sup>2</sup> but it is expected that such inducers could substantially decrease etizolam concentrations, possibly resulting in diminished etizolam effectiveness.<br><br>The precise mechanism for the interaction appears to be increased metabolism of etizolam via CYP3A4 (and possibly by CYP2C9 and/or CYP2C19, which are also involved in etizolam metabolism and which may also be induced by carbamazepine and other inducers of drug metabolism).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kondo S, Fukasawa T, Yasui-Furukori N, et al. Induction of the metabolism of etizolam by carbamazepine in humans. <i>Eur J Clin Pharmacol</i>. 2005;61(3):185-188. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15776275\">[PubMed 15776275]</a></p>\n<p>2. Depas (etizolam) [Japan Pharmaceutical Reference]. Osaka, Japan: Mitsubishi Tanabe Pharma Corporation; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9904":"<p><b>Title</b> Gefitinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Closely monitor for evidence of gefitinib-related adverse effects or toxicity if used with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Gefitinib AUC was an average of 61% to 78% higher with concurrent use of the strong CYP3A4 inhibitor itraconazole in a study of 48 healthy volunteers who received gefitinib (250 mg or 500 mg single dose on day 4) together with itraconazole (200 mg/day on days 1-12).<sup>1</sup> The clinical significance of this interaction is uncertain.<br><br>The likely mechanism for this interaction is itraconazole inhibition of the CYP3A4-mediated metabolism of gefitinib, which is metabolized by both CYP3A4 and CYP2D6.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. <i>Clin Pharmacokinet</i>. 2005;44(10):1067-1081. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16176119\">[PubMed 16176119]</a></p>\n<p>2. Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9905":"<p><b>Title</b> Influenza Virus Vaccine (Inactivated) / HMG-CoA Reductase Inhibitors (Statins)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> HMG-CoA Reductase Inhibitors (Statins) may diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> In a post-hoc analysis of a clinical study investigating the impact of an adjuvant agent on trivalent inactivated influenza vaccine immunogenicity in patients over 65 years of age, patients receiving statin medications had average influenza A(H1N1), A(H3N3), and B titers 22 days following vaccination that were 38%, 67%, and 38% lower, respectively, than those of patients not receiving statin medications (analysis adjusted for age, sex, presence of high-risk medical conditions, administration of the experimental adjuvant, and pre-vaccine titer).<sup>1</sup> In a retrospective review of database records maintained by a managed care organization, among patients at least 45 years of age who received non-live/attenuated influenza vaccination before December 31 of an influenza season (between 2002 and 2011), those who filled a statin prescription before September 1 of the influenza season at an in-network pharmacy had a higher incidence rate of medically-attended acute respiratory illness during periods of widespread influenza circulation (per International Classification of Diseases [ICD]-9 code; analysis adjusted for incidence rate when no influenza was circulating, age, comorbidities, pneumococcal vaccination, and well-person visits during the influenza season).<sup>2</sup><br><br>Data from these studies may highlight a link between statin use and diminished influenza vaccine response. However, such a link remains questionable due to several limitations of the available data (eg, the lack of mechanistic basis for an interaction, and several methodologic shortcomings of the analyses, including the potential for uncontrolled biases and reliance on imprecise exposure and outcome measures). Risk minimization strategies have not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of statins on influenza vaccine response in elderly individuals [published online October 28, 2015]. <i>J Infect Dis</i>. doi:10.1093/infdis/jiv456. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26516142\">[PubMed 26516142]</a></p>\n<p>2. Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, Orenstein WA. Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness [published online October 28, 2015]. <i>J Infect Dis</i>. doi:10.1093/infdis/jiv457. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26516141\">[PubMed 26516141]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9906":"<p><b>Title</b> Buprenorphine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Buprenorphine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Extra caution and close monitoring for evidence of increased or prolonged buprenorphine effects (e.g., respiratory depression, sedation, etc.) is recommended with any concurrent use of buprenorphine with a strong CYP3A4 inhibitor. Dose reductions of buprenorphine may be needed. After discontinuation of the CYP3A4 inhibitor, buprenorphine concentrations would be expected to decrease, possibly resulting in reduced effectiveness and/or precipitation of opioid withdrawal. Close monitoring and possible dose adjustment may be required following discontinuation of any strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The buprenorphine AUC and maximum serum concentration were an average of 1.9- and 1.6-fold higher, respectively, when sublingual buprenorphine was administered together with the strong CYP3A4 inhibitors atazanavir or atazanavir/ritonavir according to data in buprenorphine prescribing information.<sup>1</sup> Conversely, concomitant use of transdermal buprenorphine (10 mcg/hr) with the strong CYP3A4 inhibitor ketoconazole (200 mg twice/day for 11 days) was not associated with any significant change in buprenorphine exposure.<sup>2</sup><br><br>The reason for these discrepant findings is unclear. Sublingual and buccal routes may be more prone to such interactions, as CYP3A4 inhibitors could increase the bioavailability of any swallowed buprenorphine. Also, atazanavir is a UGT1A1 inhibitor and may additionally be interacting via inhibition of UGT1A1, as buprenorphine also undergoes glucuronidation. This seems less likely as an explanation as ketoconazole is also a UGT1A1 inhibitor.<br><br>The labeling for each buprenorphine product does caution that strong CYP3A4 inhibitors may increase the opioid effects and that dose reduction may be needed.<sup>1,3,4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Butrans (buprenorphine) [prescribing information]. Stamford, CT: Purdue Pharma L.P.; June 2014.</p>\n<p>2. Kapil RP, Cipriano A, Michels GH, et al. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. <i>Clin Drug Investig</i>. 2012;32(9):583-592. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22845044\">[PubMed 22845044]</a></p>\n<p>3. Belbuca (buprenorphine) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc.; October 2015.</p>\n<p>4. Subutex (buprenorphine) [prescribing information]. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; December 2011.</p>\n<p>5. Bunavail (buprenorphine and naloxone) [prescribing information]. Raleigh, NC: BioDelivery Sciences International, Inc.; June 2014.</p>\n<p>6. Suboxone (buprenorphine and naloxone) [prescribing information]. Richmond, VA: Indivior Inc.; September 2015.</p>\n<p>7. Zubsolv (buprenorphine and naloxone) [prescribing information]. Morristown, NJ: Orexo US, Inc.; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9907":"<p><b>Title</b> Buprenorphine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Buprenorphine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Extra caution and close monitoring for evidence of decreased buprenorphine effects and/or the precipitation of opioid withdrawal is recommended with any concurrent use of buprenorphine with a strong CYP3A4 inducer. Buprenorphine dose increases may be needed. After discontinuation of the CYP3A4 inducer, buprenorphine concentrations would be expected to increase, possibly resulting in prolonged or increased opioid effects. Close monitoring and possible dose adjustment may be required following discontinuation of any strong CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Specific data concerning such combinations are not available, but the labeling for each buprenorphine product does caution that strong CYP3A4 inducers may decrease the opioid effects and/or precipitate opioid withdrawal, and that buprenorphine dose increases may be needed if this combination is used.<sup>1,2,3,4,5,6</sup><br><br>The likely mechanism for this possible interaction is increased buprenorphine metabolism via induction of CYP3A4, which is primarily responsible for the primary route of buprenorphine metabolism (N-dealkylation to norbuprenorphine).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Butrans (buprenorphine) [prescribing information]. Stamford, CT: Purdue Pharma L.P.; June 2014.</p>\n<p>2. Belbuca (buprenorphine) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc.; October 2015.</p>\n<p>3. Subutex (buprenorphine) [prescribing information]. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; December 2011.</p>\n<p>4. Bunavail (buprenorphine and naloxone) [prescribing information]. Raleigh, NC: BioDelivery Sciences International, Inc.; June 2014.</p>\n<p>5. Suboxone (buprenorphine and naloxone) [prescribing information]. Richmond, VA: Indivior Inc.; September 2015.</p>\n<p>6. Zubsolv (buprenorphine and naloxone) [prescribing information]. Morristown, NJ: Orexo US, Inc.; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9908":"<p><b>Title</b> Indacaterol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Indacaterol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The indacaterol AUC was increased by an average of 1.6- to 2-fold with concurrent use of the strong CYP3A4 inhibitors ketoconazole (200 mg twice/day for 7 days) and ritonavir (300 mg twice/day for 7.5 days).<sup>1,2,3,4</sup> Similarly, the indacaterol AUC was increased by an average of 1.4- to 2-fold with the moderate CYP3A4 inhibitors erythromycin (400 mg four times/day for 7 days) and verapamil (80 mg three times/day for 4 days).<sup>1,2,3,4</sup><br><br>According to indacaterol labeling, such increases in indacaterol exposure are unlikely to require any dose adjustment.<sup>1,2,3,4</sup><br><br>The primary mechanism for this interaction is likely inhibition of the CYP3A4-mediated metabolism of indacaterol. Inhibition of efflux via p-glycoprotein may also contribute to the observed interactions as indacaterol is thought to be a p-glycoprotein substrate and the studied CYP3A4 inhibitors are all inhibitor of p-glycoprotein.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Arcapta Neohaler (indacaterol) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2012.</p>\n<p>2. Onbrez Breezhaler (indacaterol) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; January 2015.</p>\n<p>3. Utibron Neohaler (indacaterol and glycopyrrolate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.</p>\n<p>4. Ultibro Breezhaler (indacaterol and glycopyrronium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9911":"<p><b>Title</b> Clarithromycin / TraZODone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> TraZODone may enhance the QTc-prolonging effect of Clarithromycin. Clarithromycin may increase the serum concentration of TraZODone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider an alternative to this combination whenever possible. If combined, use a lower trazodone dose and monitor for increased trazodone effects (eg, sedation, QTc prolongation) if clarithromycin is initiated/dose increased, and decreased effects if clarithromycin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In 10 healthy volunteers, the AUC and maximum serum concentration of trazodone (50 mg single dose) increased 99% and 35%, respectively, when coadministered with clarithromycin 500 mg (4 doses given over 32 hours).<sup>1</sup> Self-reported and observer-reported sedation scores were increased with the combination compared with those of trazodone alone.<sup>1</sup> <br><br>Trazodone prescribing information states that concomitant use of trazodone and a potent CYP3A4 inhibitor (eg, clarithromycin) may lead to increased trazodone serum levels and a greater risk of adverse events (eg, sedation, QTc prolongation).<sup>2</sup> Use of a lower trazodone dose should be considered if these agents are combined. <br><br>The mechanism of this interaction is likely clarithromycin inhibition of CYP3A4, an enzyme responsible for trazodone metabolism. Additionally, both clarithromycin and trazodone have been reported to prolong the QTc interval, so their combined use may result in additive QTc prolongation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. <i>Clin Pharmacol Ther</i>. 2009;85(6):644-650. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19242403\">[PubMed 19242403]</a></p>\n<p>2. Oleptro (trazodone) [prescribing information]. Gaithersburg, MD: Angelini Pharma Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9912":"<p><b>Title</b> PARoxetine / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clarithromycin may enhance the adverse/toxic effect of PARoxetine. Clarithromycin may enhance the QTc-prolonging effect of PARoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for QTc prolongation and increased paroxetine effects/toxicity (eg, serotonin syndrome) if combined with clarithromycin.</p> \n<p><b>Discussion</b> A 36-year-old patient (stable for 3 months on low-dose paroxetine 10 mg daily) developed symptoms of serotonin syndrome (eg, acute ocular clonus, akathisia, fever) after receiving four doses of clarithromycin (500 mg twice daily).<sup>1</sup> Within 24 hours of clarithromycin discontinuation, the symptoms improved.<br><br>The mechanism of this interaction is currently unknown. Both clarithromycin and paroxetine have been reported to prolong the QTc interval, so their combined use may result in additive QTc prolongation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jaber BL, Lobon LF, Madias NE. The serotonin syndrome complicating co-prescription of paroxetine and clarithromycin. <i>Am J Med</i>. 2006;119(4):e3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16564762\">[PubMed 16564762]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9913":"<p><b>Title</b> FLUoxetine / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Clarithromycin may enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of clarithromycin and fluoxetine.</p> \n<p><b>Discussion</b> A 53-year-old patient (stable for 16 months on fluoxetine 80 mg daily and 45 months on nitrazepam 10 mg daily) developed psychosis and delirium after receiving clarithromycin (250 mg twice daily).<sup>1</sup> Within 36 hours of discontinuing all three medications, the patient’s mental state returned to normal. His symptoms resolved completely and did not recur with fluoxetine and nitrazepam reinitiation.<sup>1</sup> Similarly, an 89-year-old patient (stable for 2 months on fluoxetine 20 mg daily) developed symptoms of serotonin syndrome (eg, confusion, hyperthermia, diaphoresis, muscle rigidity) shortly after starting clarithromycin therapy.<sup>2</sup> Her symptoms improved approximately 72 hours after discontinuation of both medications.<sup>2</sup><br><br>The mechanism of this pharmacokinetic interaction is unknown, but clarithromycin inhibition of CYP3A4, an enzyme that is partially responsible for fluoxetine metabolism, may contribute. Since both clarithromycin and fluoxetine may prolong the QTc interval, their combined use may result in additive QTc-prolongation. Concomitant use should be avoided.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pollak PT, Sketris IS, MacKenzie SL, Hewlett TJ. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. <i>Ann Pharmacother</i>. 1995;29(5):486-488. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7655131\">[PubMed 7655131]</a></p>\n<p>2. Misselbrook GP, Shekhar R. Serotonin syndrome: an unusual cause of acute confusion and fever in the elderly. <i>Acute Med</i>. 2011;10(4):206-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22111101\">[PubMed 22111101]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9914":"<p><b>Title</b> Sertraline / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Systemic) may enhance the adverse/toxic effect of Sertraline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of sertraline if combined with erythromycin.</p> \n<p><b>Discussion</b> A 12-year-old patient (stable for 5 weeks on sertraline 37.5 mg daily) experienced symptoms of serotonin syndrome (eg, panic, restlessness, agitation, confusion, tremors, and paresthesias) within 2 weeks of starting a course of erythromycin (200 mg twice daily).<sup>1</sup> Approximately 72 hours after discontinuation of both erythromycin and sertraline, the symptoms improved. No serum sertraline concentrations were reported.<sup>1</sup> In contrast, one other case report describes a 15-year-old patient (stable for 3 years on sertraline 50 mg daily) who experienced symptoms suggestive of serotonin syndrome (eg, hypertension, anxiety, upper extremity shaking, headache) 1 day after starting erythromycin therapy.<sup>2</sup> However, he was ultimately diagnosed with conversion disorder and the diagnosis of serotonin syndrome, and evidence of a drug interaction, was excluded.<sup>2</sup><br><br>The mechanism of this interaction is unknown, but erythromycin inhibition of CYP3A4, an enzyme that is partially responsible for sertraline metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. <i>Pharmacotherapy</i>. 1999;19(7):894-896. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10417041\">[PubMed 10417041]</a></p>\n<p>2. Nisbet BC, Penfil S. Conversion disorder mimicking serotonin syndrome in an adolescent taking sertraline. <i>Del Med J</i>. 2008;80(4):141-144. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18512641\">[PubMed 18512641]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9915":"<p><b>Title</b> Acyclovir-Valacyclovir / Tenofovir Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acyclovir-Valacyclovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of both agents if acyclovir or valacyclovir is used in combination with a tenofovir-containing product.</p>\n<div>\n <p><b>Acyclovir-Valacyclovir Interacting Members</b> Acyclovir (Systemic), ValACYclovir</p>\n <p><b>Tenofovir Products Interacting Members</b> Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> Tenofovir US prescribing information notes that concomitant administration with drugs that are eliminated by active tubular secretion may increase the serum concentrations of either tenofovir or the coadministered drug.<sup>1</sup> Tenofovir is primarily excreted by this mechanism, and would thus compete with other agents. Examples specifically cited in the package labeling include: cidofovir, acyclovir, valacyclovir, ganciclovir, and valganciclovir.<br><br>The exact mechanisms of renal excretion and renal toxicity of tenofovir are poorly understood. Mechanistic and pharmacogenetic studies have suggested a role of MRP2 (gene: ABCC2),<sup>2</sup> MRP4 (gene: ABCC4),<sup>3,4</sup> and OAT1 (gene: SLC22A6)<sup>5,6,7</sup> in tenofovir renal disposition and toxicity, but the true contributions of these factors to tenofovir toxicity and their potential contribution to interactions with other agents remain unresolved.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viread (tenofovir disoproxil fumarate). Foster City, CA: Gilead Sciences, Inc, March 2010.</p>\n<p>2. Rodriguez-Novoa S, Labarga P, Soriano V, et al, “Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study,” <i>Clin Infect Dis</i>, 2009, 48(11):e108-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19400747\">[PubMed 19400747]</a></p>\n<p>3. Imaoka T, Kusuhara H, Adachi M, et al, “Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir,” <i>Mol Pharmacol</i>, 2007, 71(2):619-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110501\">[PubMed 17110501]</a></p>\n<p>4. Ray AS, Cihlar T, Robinson KL, et al, “Mechanism of Active Renal Tubular Efflux of Tenofovir,” <i>Antimicrob Agents Chemother</i>, 2006, 50(10):3297-304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17005808\">[PubMed 17005808]</a></p>\n<p>5. Uwai Y, Ida H, Tsuji Y, et al, “Renal Transport of Adefovir, Cidofovir, and Tenofovir by SLC22A Family Members (hOAT1, hOAT3, and hOCT2),” <i>Pharm Res</i>, 2007, 24(4):811-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17372702\">[PubMed 17372702]</a></p>\n<p>6. Bleasby K, Hall LA, Perry JL, et al, “Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6),” <i>J Pharmacol Exp Ther</i>, 2005, 314(2):923-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15914676\">[PubMed 15914676]</a></p>\n<p>7. Cihlar T, Ho ES, Lin DC, et al, “Human Renal Organic Anion Transporter 1 (hOAT1) and its Role in the Nephrotoxicity of Antiviral Nucleotide Analogs,” <i>Nucleosides Nucleotides Nucleic Acids</i>, 2001, 20(4-7):641-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11563082\">[PubMed 11563082]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9916":"<p><b>Title</b> Tenofovir Products / Adefovir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Adefovir may diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of adefovir and tenofovir products.</p>\n<div>\n <p><b>Tenofovir Products Interacting Members</b> Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> US prescribing information for tenofovir products recommends avoiding concomitant use with adefovir dipivoxil.<sup>1</sup> <br><br>Tenofovir (active drug) and adefovir (active drug) are primarily renally eliminated via both glomerular filtration and active tubular secretion,<sup>1,2</sup> and there is at least a potential for increased levels/effects of either agent with their concomitant use due to competition for active tubular secretion. This potential interaction was evaluated in an 8 day open-label study of healthy adults (n=22).<sup>3</sup> Adefovir dipivoxil (10mg daily on days 1 and 8) was administered along with tenofovir disoproxil fumarate (300mg daily on days 2 through 8). Adefovir AUC decreased an average of 12%, but no other significant changes in adefovir or tenofovir pharmacokinetics were observed.<br><br>Possibly of greater significance than a potential pharmacokinetic interaction are data that suggest acquisition of specific adefovir-associate mutations by the hepatitis B virus (HBV) may lead to marked reduction in susceptibility to tenofovir.<sup>1</sup> According to the tenofovir disoproxil prescribing information, HBV strains with the adefovir-associated rtA181V or rtN236T mutations exhibited a 2.9- to 10-fold decrease in susceptibility to tenofovir (vs. wild-type HBV).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viread (tenofovir disoproxil). Foster City, CA: Gilead Sciences, Inc., September 2011.</p>\n<p>2. Prescribing information. Hepsera (adefovir dipivoxil). Foster City, CA: Gilead Sciences, Inc., May 2008.</p>\n<p>3. Kearney BP, Srinivasan R, Cheng AK, et al, “Systemic and Renal Pharmacokinetics of Adefovir and Tenofovir Upon Coadministration,” <i>J Clin Pharmacol</i>, 2005, 45:935-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16027404\">[PubMed 16027404]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9917":"<p><b>Title</b> Aminoglycosides / Tenofovir Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of both agents if an aminoglycoside antibiotic is used in combination with a tenofovir-containing product.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n <p><b>Tenofovir Products Interacting Members</b> Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> Tenofovir US prescribing information notes that concomitant administration with drugs that are eliminated by active tubular secretion may increase the serum concentrations of either tenofovir or the coadministered drug.<sup>1</sup> Tenofovir is primarily excreted by this mechanism, and would thus compete with other agents. Examples specifically cited in the package labeling include: cidofovir, acyclovir, valacyclovir, ganciclovir, and valganciclovir.<br><br>The exact mechanisms of renal excretion and renal toxicity of tenofovir are poorly understood. Mechanistic and pharmacogenetic studies have suggested a role of MRP2 (gene: ABCC2),<sup>2</sup> MRP4 (gene: ABCC4),<sup>3,4</sup> and OAT1 (gene: SLC22A6)<sup>5,6,7</sup> in tenofovir renal disposition and toxicity, but the true contributions of these factors to tenofovir toxicity and their potential contribution to interactions with other agents remain unresolved.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viread (tenofovir). Foster City, CA: Gilead Sciences, Inc, March 2010.</p>\n<p>2. Rodriguez-Novoa S, Labarga P, Soriano V, et al, “Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study,” <i>Clin Infect Dis</i>, 2009, 48(11):e108-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19400747\">[PubMed 19400747]</a></p>\n<p>3. Imaoka T, Kusuhara H, Adachi M, et al, “Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir,” <i>Mol Pharmacol</i>, 2007, 71(2):619-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110501\">[PubMed 17110501]</a></p>\n<p>4. Ray AS, Cihlar T, Robinson KL, et al, “Mechanism of Active Renal Tubular Efflux of Tenofovir,” <i>Antimicrob Agents Chemother</i>, 2006, 50(10):3297-304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17005808\">[PubMed 17005808]</a></p>\n<p>5. Uwai Y, Ida H, Tsuji Y, et al, “Renal Transport of Adefovir, Cidofovir, and Tenofovir by SLC22A Family Members (hOAT1, hOAT3, and hOCT2),” <i>Pharm Res</i>, 2007, 24(4):811-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17372702\">[PubMed 17372702]</a></p>\n<p>6. Bleasby K, Hall LA, Perry JL, et al, “Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6),” <i>J Pharmacol Exp Ther</i>, 2005, 314(2):923-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15914676\">[PubMed 15914676]</a></p>\n<p>7. Cihlar T, Ho ES, Lin DC, et al, “Human Renal Organic Anion Transporter 1 (hOAT1) and its Role in the Nephrotoxicity of Antiviral Nucleotide Analogs,” <i>Nucleosides Nucleotides Nucleic Acids</i>, 2001, 20(4-7):641-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11563082\">[PubMed 11563082]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9918":"<p><b>Title</b> Cidofovir / Tenofovir Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cidofovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of both agents if cidofovir is used in combination with a tenofovir-containing product.</p>\n<div>\n <p><b>Tenofovir Products Interacting Members</b> Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> Tenofovir US prescribing information notes that concomitant administration with drugs that are eliminated by active tubular secretion may increase the serum concentrations of either tenofovir or the coadministered drug.<sup>1</sup> Tenofovir is primarily excreted by this mechanism, and would thus compete with other agents. Examples specifically cited in the package labeling include: cidofovir, acyclovir, valacyclovir, ganciclovir, and valganciclovir.<br><br>The exact mechanisms of renal excretion and renal toxicity of tenofovir are poorly understood. Mechanistic and pharmacogenetic studies have suggested a role of MRP2 (gene: ABCC2),<sup>2</sup> MRP4 (gene: ABCC4),<sup>3,4</sup> and OAT1 (gene: SLC22A6)<sup>5,6,7</sup> in tenofovir renal disposition and toxicity, but the true contributions of these factors to tenofovir toxicity and their potential contribution to interactions with other agents remain unresolved.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viread (tenofovir). Foster City, CA: Gilead Sciences, Inc, March 2010.</p>\n<p>2. Rodriguez-Novoa S, Labarga P, Soriano V, et al, “Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study,” <i>Clin Infect Dis</i>, 2009, 48(11):e108-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19400747\">[PubMed 19400747]</a></p>\n<p>3. Imaoka T, Kusuhara H, Adachi M, et al, “Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir,” <i>Mol Pharmacol</i>, 2007, 71(2):619-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110501\">[PubMed 17110501]</a></p>\n<p>4. Ray AS, Cihlar T, Robinson KL, et al, “Mechanism of Active Renal Tubular Efflux of Tenofovir,” <i>Antimicrob Agents Chemother</i>, 2006, 50(10):3297-304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17005808\">[PubMed 17005808]</a></p>\n<p>5. Uwai Y, Ida H, Tsuji Y, et al, “Renal Transport of Adefovir, Cidofovir, and Tenofovir by SLC22A Family Members (hOAT1, hOAT3, and hOCT2),” <i>Pharm Res</i>, 2007, 24(4):811-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17372702\">[PubMed 17372702]</a></p>\n<p>6. Bleasby K, Hall LA, Perry JL, et al, “Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6),” <i>J Pharmacol Exp Ther</i>, 2005, 314(2):923-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15914676\">[PubMed 15914676]</a></p>\n<p>7. Cihlar T, Ho ES, Lin DC, et al, “Human Renal Organic Anion Transporter 1 (hOAT1) and its Role in the Nephrotoxicity of Antiviral Nucleotide Analogs,” <i>Nucleosides Nucleotides Nucleic Acids</i>, 2001, 20(4-7):641-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11563082\">[PubMed 11563082]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9919":"<p><b>Title</b> Tenofovir Products / Cobicistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: These combinations should be avoided in patients with certain levels of renal impairment (see Management for details).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may enhance the adverse/toxic effect of Tenofovir Products. More specifically, cobicistat may impair proper tenofovir monitoring and dosing. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of cobicistat and tenofovir (single-agent) in patients with an estimated creatinine clearance less than 70 mL/min. Avoid initiation of the 4-drug combination product containing cobicistat and tenofovir disoproxil fumarate (in addition to elvitegravir and emtricitabine) in patients with an estimated creatinine clearance less than 70 mL/min, and discontinue the combination if the estimated creatinine clearance decreases to less than 50 mL/min. Avoid use of the 4-drug combination product containing cobicistat and tenofovir alafenamide (in addition to elvitegravir and emtricitabine) in patients with estimated creatinine clearance less than 30 mL/min. Note that cobicistat may increase serum creatinine without altering glomerular function, decreasing the reliability of serum creatinine-based estimates of renal function. Monitor urine glucose and urine protein at baseline and periodically during therapy, as well as patient response to tenofovir with any use of cobicistat. Serum phosphorus should also be monitored in patients at risk for or with evidence of renal dysfunction at baseline. Any evidence of musculoskeletal pain, weakness, or fractures may indicate possible tenofovir-related kidney damage, necessitating evaluation of renal function.</p>\n<div>\n <p><b>Tenofovir Products Interacting Members</b> Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> The prescribing information for several cobicistat-containing products cautions that concurrent use with tenofovir is not recommended in patients with an estimated creatinine clearance of less than 70 mL/min.<sup>1,2,3</sup> Prescribing information for the combination product containing cobicistat and tenofovir disoproxil fumarate (in addition to elvitegravir and emtricitabine) recommends avoiding its initiation in patients with estimated creatinine clearance of less than 70 mL/min and discontinuation of the combination if the estimated creatinine clearance decreases to less than 50 mL/min.<sup>4</sup> In a similar combination product containing tenofovir alafenamide instead of , use is not recommended for patients with estimated creatinine clearance less than 30 mL/min.<sup>5</sup> Because tenofovir is renally eliminated, with dose adjustments for single-agent tenofovir recommended in patients with an estimated creatinine clearance of less than 50 mL/min, and because its use has been associated with renal dysfunction, monitoring of renal function both prior to and during treatment with tenofovir is recommended.<sup>6</sup> Cobicistat may inhibit the renal tubular secretion of creatinine, resulting in an increase in serum creatinine despite no actual change in glomerular function.<sup>1,2,3,4,5</sup> This effect may alter the monitoring of renal function and affect decision-making for dose adjustment of drugs whose dosing is sensitive to renal function.<br><br>An in vitro study examining the ability of cobicistat to alter the renal transport of tenofovir found that supratherapeutic concentrations of cobicistat did not significantly alter the transport of tenofovir.<sup>7</sup> These data suggest that while cobicistat may complicate tenofovir therapy by impairing any serum creatinine-based ability to monitor therapy and/or adjust tenofovir doses, cobicistat may not directly alter tenofovir pharmacokinetics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; September 2014.</p>\n<p>2. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>3. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; August 2014.</p>\n<p>5. <i>Genvoya</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>6. <i>Viread</i> (tenofovir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; October 2013.</p>\n<p>7. Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. <i>Antimicrob Agents Chemother</i>. 2013;57(10):4982-4989. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23896476\">[PubMed 23896476]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9920":"<p><b>Title</b> Tenofovir Products / Diclofenac (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Diclofenac (Systemic) may enhance the nephrotoxic effect of Tenofovir Products. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Diclofenac may increase the risk for tenofovir-associated nephrotoxicity, and alternatives to this combination should be used whenever possible. Evidence suggests that other NSAIDs may also be capable of interacting with tenofovir, and the tenofovir prescribing information recommends avoiding use of with high-dose or multiple NSAIDs due to this risk. Alternative medications should be considered when possible. NSAIDs should be used with caution in patients treated with tenofovir and close monitoring for evidence of renal dysfunction is advised.</p>\n<div>\n <p><b>Tenofovir Products Interacting Members</b> Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> A retrospective analysis of 89 HIV-positive patients given diclofenac concomitantly with either tenofovir disoproxil fumarate (TDF) or a TDF-sparing combination antiretroviral therapy (cART) regimen found that acute kidney injury (AKI) developed in 13 (14.6%) of the 61 patients on TDF shortly after initiation of the NSAID diclofenac, but there were no incidences of AKI in the 28 patients on TDF-sparing cART.<sup>1</sup> All patients who developed AKI had previously normal and stable renal function. A cohort study involving HIV-positive patients receiving TDF for at least one year compared the renal function of patients coadministered NSAIDs (primarily diclofenac or ibuprofen) to those not receiving NSAIDs.<sup>2</sup> Patients with the highest exposure to NSAIDs (median of 5 defined daily doses (DDDs)/month) had an increased risk of developing more than a 25% decline in glomerular filtration rate (OR 2.81; 95% CI 1.21 to 6.49).<sup>2</sup><br><br>Similarly, a case report described a 54-year-old, HIV-positive female patient on stable tenofovir therapy who was admitted with polyuria, mental status changes, and severe metabolic acidosis.<sup>3</sup> Five days prior to admission, the patient was started on diclofenac for persistent lower limb pain. Serum laboratories and a kidney-biopsy were both consistent with tenofovir-associated AKI. Her anti-HIV therapy (including tenofovir) and diclofenac were discontinued, and her kidney function improved.<br><br>The precise mechanism(s) of this interaction is not fully understood. AKI in patients receiving anti-HIV therapy has an incidence of 2.7 to 5.9 per 100 HIV-positive outpatients.<sup>4</sup> Because tenofovir is primarily excreted through the kidneys tenofovir product labeling recommends avoiding medications that may decrease renal function or compete for active secretion sites as this may increase tenofovir serum concentrations.<sup>5</sup> Tenofovir-associated nephrotoxicity is likely caused by proximal tubular injury.<sup>1</sup> Tenofovir is eliminated unchanged primarily through glomerular filtration (70-80%). The proximal tubular cells take up the remainder (20-30%) through human organic anion transporter 1 (hOAT1), which is then secreted by multidrug-resistance protein (MRP), mainly MRP4.<sup>1</sup> Many NSAIDs such as diclofenac, indomethacin, celecoxib, and ibuprofen inhibit MRP4, suggesting that NSAIDs other than diclofenac may be similarly capable of interacting with tenofovir.<sup>6</sup> This may increase the accumulation of tenofovir in the proximal tubule cells, which in turn may cause or worsen proximal tubular injury. NSAIDs can also reduce glomerular filtration independently, which may also cause or contribute to decreased renal function.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bickel M, Khaykin P, Stephan C, et al. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. <i>HIV Med</i>. 2013;14(10):633-638. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23980564\">[PubMed 23980564]</a></p>\n<p>2. Rokx C, Alshangi H, Verbon A, Zietse R, Hoorn EJ, Rijnders BJ. Renal toxicity of concomitant exposure to tenofovir and inhibitors of tenofovir's renal efflux transporters in patients infected with HIV type 1. <i>J Infect Dis</i>. 2016;213(4):561-568. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26401025\">[PubMed 26401025]</a></p>\n<p>3. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M. Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction. <i>Clin Nephrol</i>. 2009;71(5):567-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19473619\">[PubMed 19473619]</a></p>\n<p>4. Franceschini N, Napravnik S, Eron JJ, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. <i>Kidney Int</i>. 2005; 67(4): 1526-1531. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15780107\">[PubMed 15780107]</a></p>\n<p>5. Viread (tenofovir) [prescribing information. Foster City, CA: Gilead Sciences Inc; February 2016.</p>\n<p>6. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. <i>Proc Natl Acad Sci U S A</i>. 2003;100(16):9244-9249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12835412\">[PubMed 12835412]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9921":"<p><b>Title</b> Ganciclovir-Valganciclovir / Tenofovir Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tenofovir Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of both agents if ganciclovir or valganciclovir is used in combination with a tenofovir-containing product.</p>\n<div>\n <p><b>Ganciclovir-Valganciclovir Interacting Members</b> Ganciclovir (Systemic), ValGANciclovir</p>\n <p><b>Tenofovir Products Interacting Members</b> Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> Tenofovir US prescribing information notes that concomitant administration with drugs that are eliminated by active tubular secretion may increase the serum concentrations of either tenofovir or the coadministered drug.<sup>1</sup> Tenofovir is primarily excreted by this mechanism, and would thus compete with other agents. Examples specifically cited in the package labeling include: cidofovir, acyclovir, valacyclovir, ganciclovir, and valganciclovir.<br><br>The exact mechanisms of renal excretion and renal toxicity of tenofovir are poorly understood. Mechanistic and pharmacogenetic studies have suggested a role of MRP2 (gene: ABCC2),<sup>2</sup> MRP4 (gene: ABCC4),<sup>3,4</sup> and OAT1 (gene: SLC22A6)<sup>5,6,7</sup> in tenofovir renal disposition and toxicity, but the true contributions of these factors to tenofovir toxicity and their potential contribution to interactions with other agents remain unresolved.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viread (tenofovir). Foster City, CA: Gilead Sciences, Inc, March 2010.</p>\n<p>2. Rodriguez-Novoa S, Labarga P, Soriano V, et al, “Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study,” <i>Clin Infect Dis</i>, 2009, 48(11):e108-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19400747\">[PubMed 19400747]</a></p>\n<p>3. Imaoka T, Kusuhara H, Adachi M, et al, “Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir,” <i>Mol Pharmacol</i>, 2007, 71(2):619-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110501\">[PubMed 17110501]</a></p>\n<p>4. Ray AS, Cihlar T, Robinson KL, et al, “Mechanism of Active Renal Tubular Efflux of Tenofovir,” <i>Antimicrob Agents Chemother</i>, 2006, 50(10):3297-304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17005808\">[PubMed 17005808]</a></p>\n<p>5. Uwai Y, Ida H, Tsuji Y, et al, “Renal Transport of Adefovir, Cidofovir, and Tenofovir by SLC22A Family Members (hOAT1, hOAT3, and hOCT2),” <i>Pharm Res</i>, 2007, 24(4):811-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17372702\">[PubMed 17372702]</a></p>\n<p>6. Bleasby K, Hall LA, Perry JL, et al, “Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6),” <i>J Pharmacol Exp Ther</i>, 2005, 314(2):923-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15914676\">[PubMed 15914676]</a></p>\n<p>7. Cihlar T, Ho ES, Lin DC, et al, “Human Renal Organic Anion Transporter 1 (hOAT1) and its Role in the Nephrotoxicity of Antiviral Nucleotide Analogs,” <i>Nucleosides Nucleotides Nucleic Acids</i>, 2001, 20(4-7):641-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11563082\">[PubMed 11563082]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9922":"<p><b>Title</b> Tenofovir Products / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of tenofovir with high-dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) when possible due to a potential risk for acute renal failure. This risk has been most clearly shown with the NSAID diclofenac, but some data suggest that other NSAIDs may also be capable of interacting with tenofovir. Consider alternatives to the combination whenever possible. NSAIDs should be used with caution in patients being treated with tenofovir and close monitoring for evidence of renal dysfunction is advised.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p><b>Tenofovir Products Interacting Members</b> Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> A retrospective analysis of 89 HIV-positive patients given diclofenac concomitantly with either tenofovir disoproxil fumarate (TDF) or a TDF-sparing combination antiretroviral therapy (cART) regimen found that acute kidney injury (AKI) developed in 13 (14.6%) of the 61 patients on TDF shortly after initiation of the NSAID diclofenac, but there were no incidences of AKI in the 28 patients on TDF-sparing cART.<sup>1</sup> All patients who developed AKI had previously normal and stable renal function. A cohort study involving HIV-positive patients receiving TDF for at least one year compared the renal function of patients coadministered NSAIDs (primarily diclofenac or ibuprofen) to those not receiving NSAIDs.<sup>2</sup> Patients with the highest exposure to NSAIDs (median of 5 defined daily doses (DDDs)/month) had an increased risk of developing more than a 25% decline in glomerular filtration rate (OR 2.81; 95% CI 1.21 to 6.49).<sup>2</sup><br><br>One case report described a 54-year-old, HIV-positive female patient on stable TDF therapy who was admitted with polyuria, mental status changes, and severe metabolic acidosis.<sup>3</sup> Five days prior to admission, the patient was started on diclofenac for persistent lower limb pain. Serum laboratories and a kidney biopsy were consistent with tenofovir-associated AKI. Her anti-HIV therapy (including tenofovir) and diclofenac were discontinued, and her kidney function improved.<sup>3</sup> Another case report describes a 57-year-old HIV-positive male patient on stable TDF therapy, who developed proximal tubular dysfunction (eg, proteinuria, normoglycemic glycosuria, abnormal phosphate excretion) 2 weeks after initiation of ibuprofen (600 mg three times daily).<sup>4</sup> Discontinuation of ibuprofen, but continued therapy with TDF, led to improved laboratory parameters within one week and eventually full renal recovery.<sup>4</sup> <br><br>The precise mechanism(s) of this interaction is not fully understood. AKI in patients receiving anti-HIV therapy has an incidence of 2.7 to 5.9 per 100 HIV-positive outpatients.<sup>5</sup> Because tenofovir is primarily excreted through the kidneys, tenofovir product labeling recommends avoiding medications that may decrease renal function or compete for active secretion sites as this may increase tenofovir serum concentrations.<sup>6</sup> Tenofovir-associated nephrotoxicity is likely caused by proximal tubular injury.<sup>1</sup> Tenofovir is eliminated unchanged primarily through glomerular filtration (70-80%). The proximal tubular cells take up the remainder (20-30%) through human organic anion transporter 1 (hOAT1), which is then secreted by multidrug-resistance protein (MRP), mainly MRP4.<sup>1</sup> Many NSAIDs such as diclofenac, indomethacin, celecoxib, and ibuprofen inhibit MRP4, suggesting that NSAIDs other than diclofenac may be similarly capable of interacting with tenofovir.<sup>7</sup> This may increase the accumulation of tenofovir in the proximal tubule cells, which in turn may cause or worsen proximal tubular injury. NSAIDs can also reduce glomerular filtration independently, which may also cause or contribute to decreased renal function.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bickel M, Khaykin P, Stephan C, et al. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. <i>HIV Med</i>. 2013;14(10):633-638. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23980564\">[PubMed 23980564]</a></p>\n<p>2. Rokx C, Alshangi H, Verbon A, Zietse R, Hoorn EJ, Rijnders BJ. Renal toxicity of concomitant exposure to tenofovir and inhibitors of tenofovir's renal efflux transporters in patients infected with HIV type 1. <i>J Infect Dis</i>. 2016;213(4):561-568. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26401025\">[PubMed 26401025]</a></p>\n<p>3. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M. Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction. <i>Clin Nephrol</i>. 2009;71(5):567-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19473619\">[PubMed 19473619]</a></p>\n<p>4. Duim AR, Rokx C, van Gorp EC, Rijnders BJ. Proximal tubular dysfunction in a HIV-1 patient with coadministered tenofovir disoproxil-fumarate and ibuprofen. <i>AIDS</i>. 2015;29(6):746-748. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25849839\">[PubMed 25849839]</a> </p>\n<p>5. Franceschini N, Napravnik S, Eron JJ, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. <i>Kidney Int</i>. 2005;67(4):1526-1531. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15780107\">[PubMed 15780107]</a></p>\n<p>6. Viread (tenofovir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2016.</p>\n<p>7. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. <i>Proc Natl Acad Sci U S A</i>. 2003;100(16):9244-9249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12835412\">[PubMed 12835412]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9923":"<p><b>Title</b> Cobimetinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of cobimetinib and strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 15 healthy volunteers described in the cobimetinib prescribing information, the strong CYP3A4 inhibitor itraconazole (200 mg once daily for 14 days) increased the cobimetinib (10 mg single dose) maximum serum concentration and AUC 3.2-fold and 6.7-fold, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely itraconazole inhibition of CYP3A4, the enzyme primarily responsible for cobimetinib metabolism. P-glycoprotein inhibition by itraconazole may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cotellic (cobimetinib) [prescribing information]. South San Francisco, CA: Genetech USA Inc; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9924":"<p><b>Title</b> Cobimetinib / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose to 20 mg daily during concomitant therapy with the moderate CYP3A4 inhibitor. Resume cobimetinib 60 mg daily once the moderate CYP3A4 inhibitor is discontinued. In patients who are already receiving reduced cobimetinib doses due to adverse reactions, strict avoidance of moderate CYP3A4 inhibitors is recommended.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 15 healthy volunteers described in the cobimetinib prescribing information, the strong CYP3A4 inhibitor itraconazole (200 mg once daily for 14 days) increased the cobimetinib (10 mg single dose) maximum serum concentration and AUC 3.2-fold and 6.7-fold, respectively.<sup>1</sup> Simulations suggest that the combination of cobimetinib 20 mg daily and short term (14 days or less) use of a moderate CYP3A4 inhibitor would result in cobimetinib concentrations similar to those of cobimetinib 60 mg daily alone.<sup>1</sup> <br><br>The mechanism of this interaction is likely inhibition of CYP3A4, the enzyme primarily responsible for cobimetinib metabolism. P-glycoprotein inhibition may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cotellic (cobimetinib) [prescribing information]. South San Francisco, CA: Genetech USA Inc; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9925":"<p><b>Title</b> Cobimetinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of cobimetinib and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> US prescribing information for cobimetinib states that based on simulations, cobimetinib exposure would decrease 83% when coadministered with a strong CYP3A4 inducer.<sup>1</sup> Concomitant use of cobimetinib and strong CYP3A4 inducers should be avoided since decreased cobimetinib exposure may lead to decreased efficacy.<sup>1</sup><br><br>CYP3A4 is the enzyme primarily responsible for cobimetinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cotellic (cobimetinib) [prescribing information]. South San Francisco, CA: Genetech USA Inc; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9926":"<p><b>Title</b> Cobimetinib / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of cobimetinib and moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> US prescribing information for cobimetinib states that based on simulations, cobimetinib exposure would decrease 73% when coadministered with a moderate CYP3A4 inducer.<sup>1</sup> Concomitant use of cobimetinib and moderate CYP3A4 inducers should be avoided since decreased cobimetinib exposure may lead to decreased efficacy.<sup>1</sup><br><br>CYP3A4 is the enzyme primarily responsible for cobimetinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cotellic (cobimetinib) [prescribing information]. South San Francisco, CA: Genetech USA Inc; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9927":"<p><b>Title</b> Aminoglycosides / Cefazedone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cefazedone may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cefazedone together with an aminoglycoside antibiotic.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> The prescribing information for cefazedone cautions that concurrent use with aminoglycosides may increase the risk for renal dysfunction.<sup>1</sup> A study in healthy volunteers using urinary alanine aminopeptidase (AAP) as an indicator of renal tubular damage found that gentamicin increased AAP elimination but that none of the studied cephalosporin antibiotics, including cefazedone, altered AAP elimination, and there was no evidence of an additive effect with combined gentamicin and cefazedone.<sup>2</sup> A review of the limited evidence supporting an increased risk of nephrotoxicity with cephalosporins and aminoglycosides has been published.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pazeron (cefazedone) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199400752. Accessed September 1, 2014.</p>\n<p>2. Mondorf AW. Investigations on the potential nephrotoxicity of cefazedone and gentamicin and of their combination, in comparison with the combination of cefazolin and cephalothin with gentamicin. <i>Arzneimittelforschung</i>. 1979;29(2a):449-452. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=582724\">[PubMed 582724]</a></p>\n<p>3. Rankin GO, Sutherland CH. Nephrotoxicity of aminoglycosides and cephalosporins in combination. <i>Adverse Drug React Acute Poisoning Rev.</i> 1989;8(2):73-88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2672726\">[PubMed 2672726]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9928":"<p><b>Title</b> Loop Diuretics / Cefazedone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cefazedone may enhance the nephrotoxic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cefazedone together with a loop diuretic, with particular caution and close monitoring with higher doses of loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> The prescribing information for cefazedone cautions that concurrent use with high-dose diuretics may increase the risk for renal dysfunction.<sup>1</sup> Loop diuretics have been associated with nephrotoxicity, and a prior study found that moderate doses of furosemide were associated with prolonged elimination of the cephalosporin antibiotic cephaloridine.<sup>2</sup> The authors of that report concluded that moderate or higher doses of loop diuretics could increase the nephrotoxicity of cephalosporin antibiotics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pazeron (cefazedone) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199400752. Accessed September 1, 2014.</p>\n<p>2. Norrby R, Stenqvist K, Elgefors B. Interaction between cephaloridine and furosemide in man. <i>Scand J Infect Dis</i>. 1976;8(3):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=968459\">[PubMed 968459]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9929":"<p><b>Title</b> Polymyxin B / Cefazedone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cefazedone may enhance the nephrotoxic effect of Polymyxin B. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cefazedone together with polymyxin B.</p> \n<p><b>Discussion</b> The prescribing information for cefazedone cautions that concurrent use with polymyxin B may increase the risk for renal dysfunction.<sup>1</sup> Specific data concerning this combination are not avaialble, but both cephalosporins and polymyxin B have been independently associated with renal dysfunction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pazeron (cefazedone) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199400752. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9930":"<p><b>Title</b> Colistimethate / Cefazedone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cefazedone may enhance the nephrotoxic effect of Colistimethate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cefazedone together with colistimethate.</p> \n<p><b>Discussion</b> The prescribing information for cefazedone cautions that concurrent use with colistimethate may increase the risk for renal dysfunction.<sup>1</sup> Specific data concerning this combination are not avaialble, but both cephalosporins and colistimethate have been independently associated with renal dysfunction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pazeron (cefazedone) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199400752. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9931":"<p><b>Title</b> Aminoglycosides / Cephradine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cephradine may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cephradine together with an aminoglycoside antibiotic.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> The prescribing information for multiple cephradine products caution that concurrent use with aminoglycosides may increase the risk for renal dysfunction.<sup>1,2</sup> A study in healthy volunteers using urinary alanine aminopeptidase (AAP) as an indicator of renal tubular damage found that gentamicin increased AAP elimination but that none of the studied cephalosporin antibiotics altered AAP elimination, and there was no evidence of an additive effect with combined gentamicin and the cephalosporin cefazedone.<sup>3</sup> A review of the limited evidence supporting an increased risk of nephrotoxicity with cephalosporins and aminoglycosides has been published.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nicef (cefradine) [summary of product characteristics]. Watford, Hertfordshire, United Kingdom: Co-Pharma Limited; March 2015.</p>\n<p>2. Broadcef (cephradine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=197700208. Accessed September 1, 2014.</p>\n<p>3. Mondorf AW. Investigations on the potential nephrotoxicity of cefazedone and gentamicin and of their combination, in comparison with the combination of cefazolin and cephalothin with gentamicin. <i>Arzneimittelforschung</i>. 1979;29(2a):449-452. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=582724\">[PubMed 582724]</a></p>\n<p>4. Rankin GO, Sutherland CH. Nephrotoxicity of aminoglycosides and cephalosporins in combination. <i>Adverse Drug React Acute Poisoning Rev.</i> 1989;8(2):73-88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2672726\">[PubMed 2672726]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9932":"<p><b>Title</b> Loop Diuretics / Cephradine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cephradine may enhance the nephrotoxic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cephradine together with a loop diuretic, with particular caution and close monitoring with higher doses of loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> The prescribing information for cephradine cautions that concurrent use with high-dose diuretics may increase the risk for renal dysfunction.<sup>1,2</sup> Loop diuretics have been associated with nephrotoxicity, and a prior study found that moderate doses of furosemide were associated with prolonged elimination of the cephalosporin antibiotic cephaloridine.<sup>3</sup> The authors of that report concluded that moderate or higher doses of loop diuretics could increase the nephrotoxicity of cephalosporin antibiotics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nicef (cefradine) [summary of product characteristics]. Watford, Hertfordshire, United Kingdom: Co-Pharma Limited; March 2015.</p>\n<p>2. Broadcef (cephradine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=197700208. Accessed September 1, 2014.</p>\n<p>3. Norrby R, Stenqvist K, Elgefors B. Interaction between cephaloridine and furosemide in man. <i>Scand J Infect Dis</i>. 1976;8(3):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=968459\">[PubMed 968459]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9933":"<p><b>Title</b> Warfarin / Benzbromarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benzbromarone may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased warfarin effects (eg, elevated INR, bleeding) if combined with benzbromarone.</p> \n<p><b>Discussion</b> In one open-label study of 31 patients on stable warfarin therapy, 13 patients were started on benzbromarone 50 mg daily for the treatment of hyperuricemia while the remaining 18 patients continued on warfarin therapy alone.<sup>1</sup> The mean warfarin dose required to maintain a therapeutic INR was approximately 35% lower in patients who received benzbromarone compared with those who received warfarin alone.<sup>1</sup> The oral clearance of S-warfarin was 65% lower in benzbromarone-treated patients while the oral clearance of R-warfarin was similar between groups.<sup>1</sup> In another study of 7 patients stable on warfarin and benzbromarone, plasma levels of racemic warfarin decreased 13% one week after benzbromarone withdrawal.<sup>2</sup><br><br>Product labeling for benzbromarone states that benzbromarone may inhibit warfarin metabolism leading to increased warfarin concentrations and effects.<sup>3</sup> Careful monitoring of INR is recommended if these agents are combined.<sup>3</sup><br><br>The mechanism of this interaction is likely benzbromarone inhibition of CYP2C9, the enzyme primarily responsible for the metabolism of S-warfarin (the more potent enantiomer).<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. <i>Clin Pharmacol Ther</i>. 1999;66(6):569-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613612\">[PubMed 10613612]</a></p>\n<p>2. Shimodaira H, Takahashi K, Kano K, Matsumoto Y, Uchida Y, Kudo T. Enhancement of anticoagulant action by warfarin-benzbromarone interaction. <i>J Clin Pharmacol</i>. 1996;36(2):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8852393\">[PubMed 8852393]</a></p>\n<p>3. Urinon (benzbromarone) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199502668. Accessed November 18, 2014.</p>\n<p>4. McGinnity DF, Tucker J, Trigg S, Riley RJ. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. <i>Drug Metab Dispos</i>. 2005;33(11):1700-1707. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16081671\">[PubMed 16081671]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9934":"<p><b>Title</b> Benzbromarone / Pyrazinamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrazinamide may diminish the therapeutic effect of Benzbromarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced benzbromarone efficacy if combined with pyrazinamide.</p> \n<p><b>Discussion</b> In a study of 4 healthy volunteers, administration of benzbromarone (200 mg single dose) significantly increased the urinary excretion of uric acid.<sup>1</sup> Administration of pyrazinamide (3 gram single dose) 3.5 hours prior to benzbromarone administration completely abolished the uricosuric effect of benzbromarone.<sup>1</sup> In another study of 6 patients with hyperuricemia, administration of benzbromarone (160 mg single dose) alone significantly increased the urinary excretion of uric acid, but when benzbromarone was combined with pyrazinamide (3 gram single dose) the uricosuric effect of benzbromarone was completely eliminated.<sup>2</sup> In contrast, another study and a case report found that coadministration of pyrazinamide did not reduce the uricosuric effect of benzbromarone.<sup>3,4</sup><br><br>Product labeling for benzbromarone states that concomitant use of pyrazinamide and benzbromarone may lead to reduced benzbromarone efficacy.<sup>5</sup><br><br>Pyrazinamide inhibits the renal tubular secretion, and subsequently excretion, of uric acid.<sup>6</sup> This action may antagonize the desired uricosuric effect of benzbromarone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Moriwaki Y, Yamamoto T, Takahashi S, Hada T, Higashino K. Analysis of uric acid transport in renal tubules using benzbromarone and pyrazinamide. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1990;28(2):84-88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2307550\">[PubMed 2307550]</a></p>\n<p>2. Sinclair DS, Fox IH. The pharmacology of hypouricemic effect of benzbromarone. <i>J Rheumatol</i>. 1975;2(4):437-445. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1206675\">[PubMed 1206675]</a></p>\n<p>3. Yamamoto T, Moriwaki Y, Takahashi S, Suda M, Agbedana EO, Higashino K. Two cases in whom pyrazinamide does not inhibit the uricosuric action of benzbromarone. <i>Nephron</i>. 1992;61(4):432-434. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1501741\">[PubMed 1501741]</a></p>\n<p>4. Sommers DK, Schoeman HS. Drug interactions with urate excretion in man. <i>Eur J Clin Pharmacol</i>. 1987;32(5):499-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3622598\">[PubMed 3622598]</a></p>\n<p>5. Urinon (benzbromarone) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199502668. Accessed November 18, 2014.</p>\n<p>6. Pyrazinamide [prescribing information]. Fort Lee, NJ: DAVA Pharmaceuticals Inc; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9935":"<p><b>Title</b> Benzbromarone / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may diminish the therapeutic effect of Benzbromarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced benzbromarone efficacy if combined with salicylates.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> In a study of 6 patients with hyperuricemia, administration of benzbromarone (160 mg single dose) alone significantly increased the urinary excretion of uric acid, but when benzbromarone was combined with aspirin (600 mg single dose) the uricosuric effect of benzbromarone was significantly reduced.<sup>1</sup> In another report, 5 patients treated with benzbromarone (80 mg daily) experienced a minor decrease in urinary excretion of uric acid when aspirin (2.7 grams per day) was added to their benzbromarone therapy.<sup>2</sup><br><br>Product labeling for benzbromarone states that concomitant use of salicylates and benzbromarone may lead to reduced benzbromarone efficacy.<sup>3</sup><br><br>The mechanism of this interaction has not been fully investigated, but salicylate inhibition of uric acid renal tubular secretion may antagonize the effects of benzbromarone.<sup>4</sup> Available evidence also suggests that co-administration of salicylates may decrease the uricosuric effects of probenecid and sulfinpyrazone.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sinclair DS, Fox IH. The pharmacology of hypouricemic effect of benzbromarone. <i>J Rheumatol</i>. 1975;2(4):437-445. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1206675\">[PubMed 1206675]</a></p>\n<p>2. Sorensen LB, Levinson DJ. Clinical evaluation of benzbromarone: a new uricosuric drug. <i>Arthritis Rheum</i>. 1976;19(2):183-190. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1259799\">[PubMed 1259799]</a></p>\n<p>3. Urinon (benzbromarone) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199502668. Accessed November 18, 2014.</p>\n<p>4. Louthrenoo W, Kasitanon N, Wichainun R, Sukitawut W. Effect of minidose aspirin on renal function and renal uric acid handling in healthy young adults. <i>J Clin Rheumatol</i>. 2002;8(6):299-304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17041398\">[PubMed 17041398]</a></p>\n<p>5. Yue TF, Dayton PG, Gutman AB. Mutual suppression of the uricosuric effects of sulfinpyrazone and salicylate: a study in interactions between drugs. <i>J Clin Invest</i>. 1963;42:1330-1339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14060403\">[PubMed 14060403]</a></p>\n<p>6. Seegmiller JE, Grayzel AI. Use of the newer uricosuric agents in the management of gout. <i>JAMA</i>. 1960;173:1076-1080. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14444480\">[PubMed 14444480]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9936":"<p><b>Title</b> Allopurinol / Benzbromarone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Benzbromarone may decrease the serum concentration of Allopurinol. Specifically, benzbromarone may decrease the serum concentration of oxypurinol, the active metabolite of allopurinol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of benzbromarone (20 mg or 100 mg daily) and allopurinol (100 mg daily) for 7 days decreased the oxypurinol (the active metabolite of allopurinol) AUC and maximum serum concentration (Cmax) 46% to 54% and 30% to 33%, respectively.<sup>1</sup> In another pharmacokinetic study of 14 patients, coadministration of benzbromarone (40 mg daily) and allopurinol (200 mg daily) for 7 days decreased the oxypurinol AUC and Cmax 41% and 36%, respectively.<sup>2</sup> The pharmacokinetic parameters of allopurinol were unaffected by benzbromarone in both studies.<sup>1,2</sup> Despite a reduction in oxypurinol concentrations, one study found that serum uric acid levels were lower with the combination of benzbromarone and allopurinol compared with those of allopurinol use alone.<sup>2</sup> In contrast, one pharmacokinetic study found that coadministration of benzbromarone (60 mg single dose) and allopurinol (300 mg single oral and IV doses) had no effect on the pharmacokinetics of allopurinol or oxypurinol.<sup>3</sup><br><br>The mechanism of this interaction is unknown, but benzbromarone may inhibit the reabsorption of oxypurinol from renal tubules, thus promoting its excretion.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Colin JN, Farinotti R, Fredj G, et al. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone. <i>Eur J Clin Pharmacol</i>. 1986;31(1):53-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3780828\">[PubMed 3780828]</a></p>\n<p>2. Muller FO, Schall R, Groenewoud G, Hundt HK, van der Merwe JC, van Dyk M. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. <i>Eur J Clin Pharmacol</i>. 1993;44(1):69-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8436158\">[PubMed 8436158]</a></p>\n<p>3. Breithaupt B, Tittel M. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. <i>Eur J Clin Pharmacol</i>. 1982;22(1):77-84. [7094977]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9937":"<p><b>Title</b> Ceftizoxime / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the nephrotoxic effect of Ceftizoxime. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using ceftizoxime together with a loop diuretic, using particular caution and close monitoring with higher doses of loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> The prescribing information for ceftizoxime cautions that concurrent use with loop diuretics may increase the risk for renal dysfunction.<sup>1</sup> Loop diuretics have been associated with nephrotoxicity, and a prior study found that moderate doses of furosemide were associated with prolonged elimination of the cephalosporin antibiotic cephaloridine.<sup>2</sup> The authors of that report concluded that moderate or higher doses of loop diuretics could increase the nephrotoxicity of cephalosporin antibiotics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ceftizoxime [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200200165. Accessed September 1, 2014.</p>\n<p>2. Norrby R, Stenqvist K, Elgefors B. Interaction between cephaloridine and furosemide in man. <i>Scand J Infect Dis</i>. 1976;8(3):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=968459\">[PubMed 968459]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9938":"<p><b>Title</b> Cefotiam / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the nephrotoxic effect of Cefotiam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient renal function closely when using cefotiam together with a loop diuretic, using particular caution and close monitoring with higher doses of loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> The prescribing information for cefotiam cautions that concurrent use with loop diuretics may increase the risk for renal dysfunction.<sup>1</sup> Loop diuretics have been associated with nephrotoxicity, and a prior study found that moderate doses of furosemide were associated with prolonged elimination of the cephalosporin antibiotic cephaloridine.<sup>2</sup> The authors of that report concluded that moderate or higher doses of loop diuretics could increase the nephrotoxicity of cephalosporin antibiotics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fontiam (cefotiam) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200903662. Accessed December 11, 2014.</p>\n<p>2. Norrby R, Stenqvist K, Elgefors B. Interaction between cephaloridine and furosemide in man. <i>Scand J Infect Dis</i>. 1976;8(3):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=968459\">[PubMed 968459]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9939":"<p><b>Title</b> Colchicine / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Colchicine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of colchicine with an antihepaciviral combination product is contraindicated.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> According to the prescribing information for the Viekira Pak and Technivie brand combination products, concurrent use of colchicine is contraindicated due to the potential for serious adverse reactions in patients with impaired renal and/or hepatic function.<sup>1,2</sup> Similarly, according to the colchicine prescribing information, colchicine is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor, such as the antihepaciviral combination products.<sup>3</sup><br><br>Data concerning these specific combinations are not presented in the labeling, but there are data concerning the use of colchicine with strong CYP3A4 inhibitors. A case-control study of 88 patients who received concurrent colchicine and the strong CYP3A4 inhibitor clarithromycin and 28 patients who received sequential colchicine and clarithromycin reported 9 (10.2%) fatalities in the concurrent group versus only 1 (3.6%) in the sequential group.<sup>4</sup> A longer duration of treatment overlap (relative risk (RR) = 2.2), baseline renal function impairment (RR = 9.1), and the development of pancytopenia (RR = 23.4) were all identified as significant predictors of a fatal interaction. Data presented in colchicine prescribing information indicate that concurrent administration of colchicine (0.6 mg single dose) with clarithromycin (250 mg twice daily for 7 days; n=23) was associated with a 282% increase in mean colchicine AUC and a 227% increase in mean colchicine maximum serum concentration (Cmax).<sup>3</sup> Data with other strong CYP3A4 inhibitors, ketoconazole (200 mg twice daily for 5 days; n=24), and ritonavir (100 mg twice daily for 5 days; n=18), show a 212% and 296% increase in colchicine AUC, respectively, and a 102% and 184% increase in colchicine Cmax, respectively.<sup>3</sup><br><br>Considering that CYP3A4 has a large role in colchicine metabolism, the likely mechanism of these interactions is inhibition of CYP3A4-dependent colchicine metabolism. However, since many CYP3A4 inhibitors are also inhibitors of p-glycoprotein-mediated transport and colchicine is a p-glycoprotein substrate, inhibition of p-glycoprotein may also be at least somewhat responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Colcrys (colchicine) [prescribing information]. Philadelphia, PA: AR Scientific, Inc., September 2010.</p>\n<p>4. Hung IF, Wu AK, Cheng VC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. <i>Clin Infect Dis</i>. 2005;41(3):291-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16007523\">[PubMed 16007523]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9940":"<p><b>Title</b> Benzbromarone / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sulfinpyrazone may diminish the therapeutic effect of Benzbromarone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a study of 6 patients with hyperuricemia, administration of benzbromarone (160 mg single dose) alone significantly increased the urinary excretion of uric acid.<sup>1</sup> Administration of sulfinpyrazone (300 mg single dose) alone also increased the urinary excretion of uric acid, but to a lesser degree than with benzbromarone.<sup>1</sup> When the drugs were administered together, the amount of uric acid secretion was similar to that with sulfinpyrazone alone.<sup>1</sup> <br><br>Product labeling for benzbromarone states that concomitant use of sulfinpyrazone and benzbromarone may lead to reduced efficacy of benzbromarone.<sup>2</sup><br><br>Sulfinpyrazone and benzbromarone are both uricosuric agents that affect the renal tubular handling of uric acid.<sup>2,3</sup> Competition for uric acid binding sites or other unknown mechanisms may lead to sulfinpyrazone antagonism of benzbromarone effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sinclair DS, Fox IH. The pharmacology of hypouricemic effect of benzbromarone. <i>J Rheumatol</i>. 1975;2(4):437-445. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1206675\">[PubMed 1206675]</a></p>\n<p>2. Urinon (benzbromarone) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199502668. Accessed November 18, 2014.</p>\n<p>3. Sulfinpyrazone [product monograph]. Toronto, Ontario, Canada: AA Pharma Inc; May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9941":"<p><b>Title</b> Tacrolimus (Systemic) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical tacrolimus response closely and frequently monitor tacrolimus serum concentrations with concurrent use of any strong CYP3A4 inhibitor. Tacrolimus dose reductions and/or prolongation of the dosing interval will likely be required. Reduce tacrolimus dose to approximately one-third of the original dose when starting concurrent posaconazole or voriconazole, and concurrent use with nelfinavir is not recommended unless the anticipated benefits outweigh the likely risks.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The average tacrolimus AUC was increased by 3- to 7.5-fold with concurrent use of the strong CYP3A4 inhibitors ketoconazole, voriconazole, and posaconazole in studies of healthy volunteers summarized in the tacrolimus prescribing information.<sup>1,2,3</sup> More dramatic changes of 17- to 70-fold increases in average tacrolimus AUC were reported with boceprevir (800 mg three times/day for 11 days) and telaprevir (750 mg three times/day for 13 days).<sup>1,2,3,4</sup> One report describes 2 female patients (aged 37 and 69 years), who each experienced acute renal failure and more than a 2.3-fold increase in tacrolimus serum concentrations after 9 doses of clarithromycin therapy (250 mg daily).<sup>5</sup> Numerous other case reports also describe patients who experienced a significant increase in tacrolimus concentrations after the addition of clarithromycin<sup>6,7,8,9</sup> and cobicistat.<sup>10,11</sup><br><br>The tacrolimus prescribing information cautions that tacrolimus dose adjustment may be needed with concurrent use of a strong CYP3A4 inhibitor but offers only general recommendations to monitor more frequently; although, a specific dose adjustment is recommended for voriconazole and posaconazole, and complete avoidance of nelfinavir is recommended.<sup>1,2,3</sup><br><br>Inhibition of CYP3A4 and/or CYP3A5 likely accounts for much of these reported changes, but inhibition of p-glycoprotein or possibly other transporters may also contribute to the observed changes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharmaceuticals US, Inc.; February 2015.</p>\n<p>2. Astagraf XL (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharmaceuticals US, Inc.; February 2014.</p>\n<p>3. Envarsus XR (tacrolimus) [prescribing information]. Edison, NJ: Veloxis Pharmaceuticals, Inc.; June 2015.</p>\n<p>4. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. <i>Hepatology</i>. 2012;56(5):1622-1630. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22576324\">[PubMed 22576324]</a></p>\n<p>5. Gomez G, Alvarez ML, Errasti P, et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. <i>Transplant Proc</i>. 1999;31(6):2250-2251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10500563\">[PubMed 10500563]</a></p>\n<p>6. Wolter K, Wagner K, Philipp T, Fritschka E. Interaction between FK 506 and clarithromycin in a renal transplant patient. <i>Eur J Clin Pharmacol</i>. 1994;47(2):207-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7532134\">[PubMed 7532134]</a></p>\n<p>7. Ibrahim RB, Abella EM, Chandrasekar PH. Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation. <i>Ann Pharmacother</i>. 2002;36(12):1971-1972. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12452763\">[PubMed 12452763]</a></p>\n<p>8. Parissis H, Gould K, Dark J. Dangerous drug interactions leading to hemolytic uremic syndrome following lung transplantation. <i>J Cardiothorac Surg</i>. 2010;5(1):70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20813025\">[PubMed 20813025]</a></p>\n<p>9. Kunicki P, Sobieszczanska-Malek M. Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. <i>Ther Drug Monit</i>. 2005;27(1): 107-108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15665756\">[PubMed 15665756]</a></p>\n<p>10. Patel SJ, Kuten SA, Musick WL, Gaber AO, Monsour HP, Knight RJ. Combination drug products for HIV - a word of caution for the transplant clinician [published online April 18, 2016. <i>Am J Transplant</i>. doi: 10.1111/ajt.13826. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27089541\">[PubMed 27089541]</a></p>\n<p>11. Han Z, Kane BM, Petty LA, Josephson MA, Sutor J, Pursell KJ. Cobicistat significantly increases tacrolimus serum concentrations in a renal transplant recipient with human immunodeficiency virus infection [published online April 3, 2016]. <i>Pharmacotherapy</i>. Doi: 10.1002/phar.1752. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27041642\">[PubMed 27041642]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9942":"<p><b>Title</b> Tacrolimus (Systemic) / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nelfinavir may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of nelfinavir with tacrolimus is not recommended unless the anticipated benefits outweigh the likely risks. If this combination must be used, a tacrolimus dose reduction will likely be necessary; monitor clinical tacrolimus response closely and frequently monitor tacrolimus serum concentrations.</p> \n<p><b>Discussion</b> The tacrolimus prescribing information warns that concurrent use of nelfinavir is not recommended unless the anticipated benefits outweigh the likely risks.<sup>1,2,3</sup><br><br>The addition of lopinavir/ritonavir (n=7) or nelfinavir (n=2) to post-liver-transplant patients with stable liver function tests and stable tacrolimus concentrations significantly decreased tacrolimus clearance.<sup>4</sup> Tacrolimus dose requirements were also significantly altered, with lopinavir/ritonavir decreasing tacrolimus dose requirements by 99% and nelfinavir decreasing tacrolimus dose requirements by 75-93%.<br><br>Inhibition of CYP3A4 and/or CYP3A5 by nelfinavir is the likely mechanism for this apparent interaction, but inhibition of p-glycoprotein or possibly other transporters may also contribute to the observed changes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharmaceuticals US, Inc.; February 2015.</p>\n<p>2. Astagraf XL (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharmaceuticals US, Inc.; February 2014.</p>\n<p>3. Envarsus XR (tacrolimus) [prescribing information]. Edison, NJ: Veloxis Pharmaceuticals, Inc.; June 2015.</p>\n<p>4. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. <i>Clin Pharmacokinet</i>. 2007;46(11):941-952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17922559\">[PubMed 17922559]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9943":"<p><b>Title</b> Osimertinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Osimertinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in osimertinib product labeling, itraconazole (200 mg twice daily x 5 days) increased the osimertinib AUC 24%.<sup>1,2</sup> Since this average increase is less than the observed interpatient variability (46%), this interaction is unlikely to be of clinical significance.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tagrisso (osimertinib) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; July 2016.</p>\n<p>2. Tagrisso (osimertinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9944":"<p><b>Title</b> Osimertinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of osimertinib and strong CYP3A4 inducers whenever possible. If combined use is unavoidable, increase the osimertinib dose to 160 mg daily. Reduce the osimertinib dose to 80 mg daily 3 weeks after discontinuation of the strong CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the osimertinib prescribing information, rifampin (600 mg daily x 21 days) decreased the osimertinib AUC 78%.<sup>1</sup><br><br>Osimertinib prescribing information states that the use of osimertinib and strong CYP3A4 inducers should be avoided whenever possible.<sup>1</sup> If concomitant use is unavoidable, increase the osimertinib dose to 160 mg daily.<sup>1</sup> The osimertinib dose should be decreased to 80 mg daily 3 weeks after the strong CYP3A4 inducer is discontinued.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tagrisso (osimertinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9947":"<p><b>Title</b> Osimertinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Osimertinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of osimertinib and St John's wort.</p> \n<p><b>Discussion</b> No clinical studies have been conducted evaluating the potential interaction between osimertinib and St John's wort, but in a pharmacokinetic study described in the osimertinib prescribing information, the strong CYP3A4 inducer rifampin (600 mg daily x 21 days) decreased the osimertinib AUC 78%.<sup>1</sup><br><br>Osimertinib prescribing information states that the use of osimertinib and St. John's wort should be avoided whenever possible.<sup>1</sup> Concomitant use may decrease osimertinib exposure and reduce its efficacy.<sup>1</sup><br><br>The mechanism of this potential interaction is due to St John's wort-mediated induction of CYP3A4, an enzyme responsible for osimertinib metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tagrisso (osimertinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9961":"<p><b>Title</b> Disopyramide / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Clarithromycin may enhance the hypoglycemic effect of Disopyramide. Clarithromycin may enhance the QTc-prolonging effect of Disopyramide. Clarithromycin may increase the serum concentration of Disopyramide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of disopyramide and clarithromycin. Concomitant use may lead to increased disopyramide concentrations, QTc prolongation, Torsades de pointes, and hypoglycemia.</p> \n<p><b>Discussion</b> Several case reports describe patients who were stabilized on disopyramide and experienced QTc prolongation,<sup>1,2,3,4</sup> Torsades de pointes (TdP),<sup>1,2,3</sup> and hypoglycemia<sup>4</sup> after initiation of clarithromycin. Serum concentrations of disopyramide were elevated or near the upper limit of normal in all cases.<sup>1,2,3,4</sup><br><br>Prescribing information for disopyramide states that inhibitors of CYP3A4 (eg, clarithromycin) may increase disopyramide levels and the risk of adverse events.<sup>5</sup> Cases of life-threatening interactions have been reported when disopyramide was given with clarithromycin.<sup>5</sup> Clarithromycin prescribing information states that use of clarithromycin should be avoided in patients taking class 1a antiarrhythmics (eg, disopyramide) due to the risk of QTc prolongation and TdP.<sup>6</sup> If these agents are combined, electrocardiogram findings, electrolytes, blood glucose, and serum disopyramide concentrations should be carefully monitored.<sup>6</sup><br><br>The mechanism of this interaction is likely clarithromycin inhibition of CYP3A4, an enzyme responsible for disopyramide metabolism. Increased disopyramide concentrations may lead to QTc prolongation, TdP, and hypoglycemia. Additionally, both clarithromycin and disopyramide are independently associated with QTc prolongation, so their effects may be additive.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. <i>Heart Dis</i>. 1999;1(4):206-207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11720625\">[PubMed 11720625]</a></p>\n<p>2. Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. <i>Pacing Clin Electrophysiol</i>. 1999;22(4 pt 1):672-674. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10234723\">[PubMed 10234723]</a></p>\n<p>3. Paar D, Terjung B, Sauerbruch T. Life-threatening interaction between clarithromycin and disopyramide. <i>Lancet</i>. 1997;349(9048):326-327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9024381\">[PubMed 9024381]</a></p>\n<p>4. Iida H, Morita T, Suzuki E, Iwasawa K, Toyo-oka T, Nakajima T. Hypoglycemia induced by interaction between clarithromycin and disopyramide. <i>Jpn Heart J</i>. 1999;40(1):91-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10370402\">[PubMed 10370402]</a></p>\n<p>5. Disopyramide ER [prescribing information]. St. Louis, MO: Ethex Corporation; February 2007.</p>\n<p>6. Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9962":"<p><b>Title</b> QUEtiapine / Sodium Polystyrene Sulfonate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sodium Polystyrene Sulfonate may decrease the serum concentration of QUEtiapine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased quetiapine concentrations and effects if given concomitantly with sodium polystyrene sulfonate. Consider separating the administration of these agents by 6 hours.</p> \n<p><b>Discussion</b> One case report describes a 49-year-old woman receiving extended-release quetiapine (800 mg daily), sodium polystyrene sulfate (15 g daily), and sevelamer (12 g daily) as an outpatient.<sup>1</sup> Upon hospital admission her serum quetiapine level was less than 20 mcg/L (therapeutic range 100 mcg/L to 500 mcg/L).<sup>1</sup> After 7 days in the hospital where her medication administration was closely monitored, her serum quetiapine level only rose to 40 mcg/L.<sup>1</sup> After initiating hemodialysis, separating the administration of sodium polystyrene sulfate and quetiapine by 10 hours, and separating the administration of sevelamer and quetiapine by 5 hours, her serum quetiapine level increased to 345 mcg/L.<sup>1</sup> An in vitro experiment found that sodium polystyrene sulfate bound 99.1% of quetiapine independent of the pH tested.<sup>1</sup> Sevelamer bound 62% to 70% of quetiapine at an elevated pH (5 to 7.4), but bound almost no quetiapine at an acidic pH (1.5).<sup>1</sup><br><br>An FDA safety communication states that due to the results of in vitro binding studies conducted with a similar potassium binding drug (patiromer), a separation of at least 6 hours should be considered between the administration of sodium polystyrene sulfate and other medications taken orally.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but sodium polystyrene sulfate may bind quetiapine in the gastrointestinal tract and inhibit its absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hoge RH, Arbouw ME, Radstake SD, van Berlo-van de Laar IR. Subtherapeutic serum quetiapine concentrations after absorption inhibition by binding resins: a case report. <i>J Clin Pharm Ther</i>. 2015;40(3):355-357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25808008\">[PubMed 25808008]</a></p>\n<p>2. FDA Drug Safety Communication. Medwatch. FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate). Food and Drug Administration website. Http://www.fda.gov/Drugs/DrugSafety/ucm468035.htm. Published October 22, 2015. Accessed November 13, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9963":"<p><b>Title</b> Glycopyrrolate (Systemic) / Amantadine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amantadine may enhance the anticholinergic effect of Glycopyrrolate (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for excessive anticholinergic effects with use of this combination. Consider reducing the dose of glycopyrrolate during concurrent use.</p> \n<p><b>Discussion</b> Glycopyrrolate prescribing information cautions that concurrent use of amantadine may enhance the anticholinergic effects of glycopyrrolate.<sup>1</sup> Clinicians are encouraged to consider reducing the glycopyrrolate dose during concurrent use.<sup>1</sup><br><br>The likely mechanism of this interaction is additive or synergistic anticholinergic effects. Although animal studies suggest little/no direct anticholinergic effects for amantadine, anticholinergic-type side effects have been noted with clinical use.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cuvposa (glycopyrrolate). Atlanta, GA: Shionogi Pharma, Inc., 07/2010.</p>\n<p>2. Prescribing information. Symmetrel (amantadine). Chadds Ford, PA:Endo Pharmaceuticals Inc., January 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9964":"<p><b>Title</b> Glycopyrrolate (Oral Inhalation) / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of inhaled glycopyrrolate with any other drugs that have anticholinergic properties. If such combinations cannot be avoided, monitor patients closely for evidence of anticholinergic-related toxicities (e.g., urinary retention, constipation, tachycardia, dry mouth, etc.).</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The labeling for inhaled glycopyrrolate products cautions that concurrent use of any other anticholinergic drugs should be avoided due to the risk for additive/excessive anticholinergic effects.<sup>1,2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Seebri Neohaler (glycopyrrolate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.</p>\n<p>2. Seebri Breezhaler (glycopyrronium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; July 2015.</p>\n<p>3. Utibron Neohaler (indacaterol and glycopyrrolate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.</p>\n<p>4. Ultibro Breezhaler (indacaterol and glycopyrronium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9965":"<p><b>Title</b> Atenolol / Glycopyrrolate (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Glycopyrrolate (Systemic) may increase the serum concentration of Atenolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs/symptoms of excessive beta-blockade (i.e., heart rate, blood pressure, bronchoconstriction) when using atentolol together with glycopyrrolate. Atenolol dose reductions may be necessary.</p> \n<p><b>Discussion</b> According to glycopyrrolate prescribing information, concurrent use with atenolol may be associated with an increase in the atenolol bioavailability, potentially leading to increased atenolol concentrations and increased beta-blockade.<sup>1</sup> It it further noted that a reduction in atenolol dose may be necessary.<br><br>The specific mechanism for this purported interaction is uncertain, but it may be related to the ability of glycopyrrolate to inhibit gastrointestinal motility and secretions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cuvposa (glycopyrrolate). Atlanta, GA: Shionogi Pharma, Inc., 07/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9966":"<p><b>Title</b> Glycopyrrolate (Oral Inhalation) / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Glycopyrrolate (Oral Inhalation). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The glycopyrrolate AUC was an average of 22% higher, and the glycopyrrolate renal clearance was an average of 23% lower, with concurrent cimetidine in a study of 20 healthy volunteers who received a dose of indacaterol (100 mcg, inhaled) alone and on day 4 of cimetidine (800 mg twice/day for 6 days).<sup>1</sup><br><br>The mechanism for this apparent interaction is uncertain but is likely cimetidine inhibition of organic cation transporters that are involved in the renal elimination of glycopyrrolate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dumitras S, Sechaud R, Drollmann A, et al. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. <i>Int J Clin Pharmacol Ther</i>. 2013;51(10):771-779. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24040847\">[PubMed 24040847]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9967":"<p><b>Title</b> Digoxin / Glycopyrrolate (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction appears to be limited to digoxin slow dissolution oral tablets.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Glycopyrrolate (Systemic) may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to digoxin closely in patients taking both glycopyrrolate and slow dissolving digoxin tablets. Specifically, monitor for signs/symptoms of digoxin toxicity.</p> \n<p><b>Discussion</b> Glycopyrrolate prescribing information cautions that digoxin serum concentration may be increased, with a corresponding increase in the risk for excessive digoxin effects/toxicity, when digoxin slow dissolving tablets are used in patients receiving glycopyrrolate.<sup>1</sup> Other oral digoxin dosage forms are less likely to interact.<br><br>The significant anticholinergic-related effects on gastric motility/activity are likely responsible for this reported interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cuvposa (glycopyrrolate). Atlanta, GA: Shionogi Pharma, Inc., 07/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9968":"<p><b>Title</b> Haloperidol / Glycopyrrolate (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Glycopyrrolate (Systemic) may decrease the serum concentration of Haloperidol. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs/symptoms of reduced clinical response to haloperidol if concurrent use with glycopyrrolate is required. When possible, consider avoiding concurrent use.</p> \n<p><b>Discussion</b> According to glycopyrrolate prescribing information, concurrent use with haloperidol may be associated with a decrease in haloperidol serum concentrations and reduced clinical effects.<sup>1</sup> If this combination can not be avoided, increased monitoring of haloperidol clinical response is warranted.<br><br>The specific mechanism for this purported interaction are uncertain, but the significant anticholinergic-related effects of glycopyrrolate on gastric motility/activity may be responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cuvposa (glycopyrrolate). Atlanta, GA: Shionogi Pharma, Inc., 07/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9969":"<p><b>Title</b> Levodopa / Glycopyrrolate (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Glycopyrrolate (Systemic) may decrease the serum concentration of Levodopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs/symptoms of reduced clinical response to levodopa if concurrent use with glycopyrrolate is required. Increased levodopa doses may be necessary.</p> \n<p><b>Discussion</b> According to glycopyrrolate prescribing information, concurrent use with levodopa may be associated with a decrease in levodopa serum concentrations and reduced clinical effects.<sup>1</sup> It is further noted that increased levodopa doses may be needed.<br><br>The specific mechanism for this purported interaction are uncertain, but the significant anticholinergic-related effects of glycopyrrolate on gastric motility/activity may be responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cuvposa (glycopyrrolate). Atlanta, GA: Shionogi Pharma, Inc., 07/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9970":"<p><b>Title</b> MetFORMIN / Glycopyrrolate (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Glycopyrrolate (Systemic) may increase the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs/symptoms of excessive response to metformin (i.e., blood glucose, signs/symptoms of hypoglycemia, etc.) when using metformin together with glycopyrrolate. Metformin dose reductions may be necessary.</p> \n<p><b>Discussion</b> According to glycopyrrolate prescribing information, concurrent use with metformin may be associated with an increase in metformin serum concentrations, potentially leading to increased metformin effects/toxicity.<sup>1</sup> It it further noted that a reduction in metformin dose may be necessary.<br><br>The specific mechanism for this purported interaction is uncertain, but it may be related to the ability of glycopyrrolate to inhibit gastrointestinal motility and secretions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cuvposa (glycopyrrolate). Atlanta, GA: Shionogi Pharma, Inc., 07/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9971":"<p><b>Title</b> Iron Salts / Sodium Polystyrene Sulfonate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered iron and orally administered sodium polystyrene sulfonate. Intravenous iron or rectal sodium polystyrene sulfonate will not participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sodium Polystyrene Sulfonate may decrease the serum concentration of Iron Salts. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> In a trial design to determine the potential therapeutic effect of sodium polystyrene sulfonate (SPS) for the treatment of iron overdose, SPS (30 g single dose) was administered 45 minutes after administration of ferrous sulfate (10 mg/kg of elemental iron) in 6 healthy volunteers.<sup>1</sup> The AUC of iron decreased 18%, but this change was not statistically significant.<sup>1</sup><br><br>An FDA safety communication states that due to the results of in vitro binding studies conducted with a similar potassium binding drug (patiromer), a separation of at least 6 hours should be considered between the administration of sodium polystyrene sulfate and other medications taken orally.<sup>2</sup> However, that warning is more applicable to medications for which there is an absence of data when combined with SPS. For oral iron salts, the effects of SPS administration on iron exposure appears minimal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shepherd G, Klein-Schwartz W, Burstein AH. Efficacy of the cation exchange resin, sodium polystyrene sulfonate, to decrease iron absorption. <i>J Toxicol Clin Toxicol</i>. 2000;38(4):389-394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10930055\">[PubMed 10930055]</a></p>\n<p>2. FDA Drug Safety Communication. Medwatch. FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate). Food and Drug Administration website. Http://www.fda.gov/Drugs/DrugSafety/ucm468035.htm. Published October 22, 2015. Accessed November 13, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9972":"<p><b>Title</b> Iron Salts / Calcium Polystyrene Sulfonate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered iron and orally administered calcium polystyrene sulfonate. Intravenous iron or rectal calcium polystyrene sulfonate will not participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Calcium Polystyrene Sulfonate may decrease the serum concentration of Iron Salts. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> In a trial design to determine the potential therapeutic effect of sodium polystyrene sulfonate (SPS) for the treatment of iron overdose, SPS (30 g single dose) was administered 45 minutes after administration of ferrous sulfate (10 mg/kg of elemental iron) in 6 healthy volunteers.<sup>1</sup> The AUC of iron decreased 18%, but this change was not statistically significant.<sup>1</sup> Similar results would be expected with the calcium form of the binding resin.<br><br>The mechanism of this potential interaction is that sodium polystyrene sulfate (and calcium polystyrene sulfonate) may bind iron in the gastrointestinal tract and inhibit its absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shepherd G, Klein-Schwartz W, Burstein AH. Efficacy of the cation exchange resin, sodium polystyrene sulfonate, to decrease iron absorption. <i>J Toxicol Clin Toxicol</i>. 2000;38(4):389-394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10930055\">[PubMed 10930055]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9973":"<p><b>Title</b> Lurasidone / EPINEPHrine (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This theoretical interaction consideration applies only in the setting of acute lurasidone overdose.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> EPINEPHrine (Systemic) may enhance the hypotensive effect of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid epinephrine in patients with hypotension and circulatory collapse caused by acute lurasidone overdose.</p> \n<p><b>Discussion</b> Lurasidone prescribing information states that epinephrine and dopamine should not be used for hypotension and circulatory collapse caused by acute lurasidone overdose, as beta stimulation could theoretically worsen hypotension brought about by lurasidone alpha blockade.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; October 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9974":"<p><b>Title</b> EPINEPHrine (Systemic) / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use epinephrine with caution in patients receiving monoamine oxidase inhibitors, and monitor blood pressure response closely.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Epinephrine US and Canadian product labeling warns that coadministration with monoamine oxidase (MAO) inhibitors may potentiate the effects of epinephrine.<sup>1,2</sup> Label warnings are stronger, advising to avoid concomitant use, when epinephrine is used in non-life threatening situations (eg, for procedural use in combination with local anesthetics, inhaled).<sup>3,4,5,6</sup> In a study of 3 healthy volunteers, epinephrine induced increases in heart rate and systolic blood pressure were enhanced (by 1.8- to 4.5-fold and 1.8- to 3-fold, respectively) in all subjects following 8 to14 days of tranylcypromine (30 mg/day).<sup>7</sup> In contrast, several reports describe a lack of clinical impact of treatment with MAO inhibitors on blood pressure effects of epinephrine (including, in one case report, ophthalmic epinephrine).<sup>8,9,10</sup><br><br>In contrast to other MAOIs, methylene blue has consistently enhanced blood pressure responses to norepinephrine or epinephrine, and/or decreased dose requirements of these drugs, in clinical studies.<sup>11,12,13,14</sup><br><br>MAOIs could theoretically inhibit the systemic clearance of epinephrine via inhibition of its MAO-dependent degradation. However, based on the preponderance of clinical data, these effects are likely minor in most patients. The more consistent effects seen with methylene blue likely relate more to its inhibitory effects on inducible nitric oxide synthases and guanylate cyclase, and/or effects on other non-MAO systems.</p> \n<p><b>Footnotes</b> </p>\n<p>1. EpiPen (epinephrine) [prescribing information]. Napa, CA: Mylan Specialty LP; August 2012. </p>\n<p>2. EpiPen (epinephrine) [product monograph]. Napa, CA: Dey Pharma LP; March 2012. </p>\n<p>3. Bupivacaine hydrochloride and epinephrine [prescribing information]. Lake Forest, IL: Hospira Inc; December 2009.</p>\n<p>4. Xylocaine (lidocaine hydrochloride and epinephrine) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; February 2010.</p>\n<p>5. Primatene (epinephrine) [prescribing information]. Madison, NJ: Wyeth Consumer Healthcare; August 2001.</p>\n<p>6. Scandonest (mepivacaine hydrochloride and adrenaline) [summary of product characteristics]. Saint-Maur-des-Fosses, France: Septodont; April 2013.</p>\n<p>7. Cuthbert MF, Vere DW. Potentiation of the cardiovascular effects of some catecholamines by a monoamine oxidase inhibitor. <i> Br J Pharmacol</i>. 1971;43(2):471P-472P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158241\">[PubMed 5158241]</a></p>\n<p>8. Barar FS, Boakes AJ, Benedikter LB, Laurence DR, Prichard BN, Teoh PC. Interactions between catecholamines and tricyclic and monoamine oxidase inhibitor antidepressive agents in man. <i>Br J Pharmacol</i>. 1971;43(2):472P-473P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158242\">[PubMed 5158242]</a></p>\n<p>9. Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. <i>Br Med J</i>. 1973;1(5849):311-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>10. Thompson DS, Sweet RA, Marzula K, Peredes JC. Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient. <i>J Clin Psychopharmacol</i>. 1997;17(4):322-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241014\">[PubMed 9241014]</a></p>\n<p>11. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. <i>Crit Care Med</i>. 2001;29(10):1860-1867. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11588440\">[PubMed 11588440]</a></p>\n<p>12. Koelzow H, Gedney JA, Baumann J, Snook NJ, Bellamy MC. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. <i>Anesth Analg</i>. 2002;94(4):824-829. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11916779\">[PubMed 11916779]</a></p>\n<p>13. Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. <i>Anesth Analg</i>. 2006;103(1):2-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16790616\">[PubMed 16790616]</a></p>\n<p>14. van Haren FM, Pickkers P, Foudraine N, Heemskerk S, Sleigh J, van der Hoeven JG. The effects of methylene blue infusion on gastric tonometry and intestinal fatty acid binding protein levels in septic shock patients. <i>J Crit Care</i>. 2010;25(2):358.e1-358.e7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20381302\">[PubMed 20381302]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9975":"<p><b>Title</b> EPINEPHrine (Oral Inhalation) / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of inhaled epinephrine and monoamine oxidase inhibitors (MAOIs). Discontinuation of the MAOI should occur at least 2 weeks prior to initiation of inhaled epinephrine.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> In a study of 3 healthy volunteers, epinephrine induced increases in heart rate and systolic blood pressure were enhanced (by 1.8- to 4.5-fold and 1.8- to 3-fold, respectively) in all subjects following 8 to14 days of tranylcypromine (30 mg/day).<sup>1</sup> In contrast, several reports describe a lack of clinical impact of treatment with MAOIs on the blood pressure effects of epinephrine (including, in one case report, ophthalmic epinephrine).<sup>2,3,4</sup><br><br>Prescribing information for inhaled epinephrine states that inhaled epinephrine should not be used in patients taking an MAOI and that MAOI therapy should be discontinued for at least 2 weeks prior to inhaled epinephrine initiation.<sup>5</sup><br><br>In contrast to other MAOIs, methylene blue has consistently enhanced blood pressure responses to norepinephrine or epinephrine, and/or decreased dose requirements of these drugs, in clinical studies.<sup>6,7,8,9</sup><br><br>MAOIs could theoretically inhibit the systemic clearance of epinephrine via inhibition of its MAO-dependent degradation. However, based on the preponderance of clinical data, these effects are likely minor in most patients. The more consistent effects seen with methylene blue likely relate more to its inhibitory effects on inducible nitric oxide synthases and guanylate cyclase, and/or effects on other non-MAO systems.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cuthbert MF, Vere DW. Potentiation of the cardiovascular effects of some catecholamines by a monoamine oxidase inhibitor. <i> Br J Pharmacol</i>. 1971;43(2):471P-472P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158241\">[PubMed 5158241]</a></p>\n<p>2. Barar FS, Boakes AJ, Benedikter LB, Laurence DR, Prichard BN, Teoh PC. Interactions between catecholamines and tricyclic and monoamine oxidase inhibitor antidepressive agents in man. <i>Br J Pharmacol</i>. 1971;43(2):472P-473P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158242\">[PubMed 5158242]</a></p>\n<p>3. Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. <i>Br Med J</i>. 1973;1(5849):311-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>4. Thompson DS, Sweet RA, Marzula K, Peredes JC. Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient. <i>J Clin Psychopharmacol</i>. 1997;17(4):322-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241014\">[PubMed 9241014]</a></p>\n<p>5. Primatene (epinephrine) [prescribing information]. Madison, NJ: Wyeth Consumer Healthcare; August 2001.</p>\n<p>6. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. <i>Crit Care Med</i>. 2001;29(10):1860-1867. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11588440\">[PubMed 11588440]</a></p>\n<p>7. Koelzow H, Gedney JA, Baumann J, Snook NJ, Bellamy MC. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. <i>Anesth Analg</i>. 2002;94(4):824-829. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11916779\">[PubMed 11916779]</a></p>\n<p>8. Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. <i>Anesth Analg</i>. 2006;103(1):2-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16790616\">[PubMed 16790616]</a></p>\n<p>9. van Haren FM, Pickkers P, Foudraine N, Heemskerk S, Sleigh J, van der Hoeven JG. The effects of methylene blue infusion on gastric tonometry and intestinal fatty acid binding protein levels in septic shock patients. <i>J Crit Care</i>. 2010;25(2):358.e1-358.e7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20381302\">[PubMed 20381302]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9976":"<p><b>Title</b> EPINEPHrine (Oral Inhalation) / Inhalational Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Oral Inhalation). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer large doses of inhaled epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower doses of epinephrine and monitor for the development of cardiac arrhythmias.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Cardiac irritability is increased when epinephrine is administered to patients receiving (or who have recently received) volatile anesthetics, leading to increased risk of cardiac arrhythmias.<sup>1,2,3,4</sup> Pulmonary absorption studies suggest that large inhaled doses (4 mg to 8 mg) may achieve systemic concentrations and effects similar to those of intravenous or intramuscular administration.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Katz RL, Matteo RS, Papper EM. The injection of epinephrine during general anesthesia with halogenated hydrocarbons and cyclopropane in man. 2. Halothane. <i>Anesthesiology</i>. 1962;23(5):597-600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14454401\">[PubMed 14454401]</a></p>\n<p>2. Johnston RR, Eger EI II, Wilson C. A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man. <i>Anesth Analg</i>. 1976;55(5):709-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=987729\">[PubMed 987729]</a></p>\n<p>3. Navarro R, Weiskopf RB, Moore MA, et al. Humans anesthetized with sevoflurane or isoflurane have similar arrhythmic response to epinephrine. <i>Anesthesiology</i>. 1994;80(3):545-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7511357\">[PubMed 7511357]</a></p>\n<p>4. Moore MA, Weiskopf RB, Eger EI 2nd, Wilson C, Lu G. Arrhythmogenic doses of epinephrine are similar during desflurane or isoflurane anesthesia in humans. <i>Anesthesiology</i>. 1993;79(5):943-947. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7694528\">[PubMed 7694528]</a></p>\n<p>5. Warren JB, Doble N, Dalton N, Ewan PW. Systemic absorption of inhaled epinephrine. <i>Clin Pharmacol Ther</i>. 1986;40(6):673-678. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3780129\">[PubMed 3780129]</a></p>\n<p>6. Breuer C, Wachall B, Gerbeth K, Abdel-Tawab M, Fuhr U. Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. <i>Eur J Clin Pharmacol</i>. 2013;69(6):1303-1310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23292159\">[PubMed 23292159]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9977":"<p><b>Title</b> EPINEPHrine (Systemic) / Inhalational Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Cardiac irritability is increased when epinephrine is administered to patients receiving (or who have recently received) volatile anesthetics, leading to increased risk of cardiac arrhythmias. Reduced and limited doses of epinephrine should be employed.<sup>1</sup> One study demonstrated that the minimum dysrhythmic dose of epinephrine (oral, submucosal administration) was 2 mcg/kg, 3.5 mcg/kg, and 5.5 mcg/kg when administered with halothane, enflurane, and isoflurane, respectively.<sup>2</sup> When administered in combination with lidocaine, the arrythmogenic effects of epinephrine with halothane appear to be attenuated (the dysrythmic dose was 3 mcg/kg).<sup>2</sup> The effects with sevoflurane and desflurane appear similar to isoflurane.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Katz RL, Matteo RS, Papper EM. The injection of epinephrine during general anesthesia with halogenated hydrocarbons and cyclopropane in man. 2. Halothane. <i>Anesthesiology</i>. 1962;23(5):597-600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14454401\">[PubMed 14454401]</a></p>\n<p>2. Johnston RR, Eger EI II, Wilson C. A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man. <i>Anesth Analg</i>. 1976;55(5):709-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=987729\">[PubMed 987729]</a></p>\n<p>3. Navarro R, Weiskopf RB, Moore MA, et al. Humans anesthetized with sevoflurane or isoflurane have similar arrhythmic response to epinephrine. <i>Anesthesiology</i>. 1994;80(3):545-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7511357\">[PubMed 7511357]</a></p>\n<p>4. Moore MA, Weiskopf RB, Eger EI 2nd, Wilson C, Lu G. Arrhythmogenic doses of epinephrine are similar during desflurane or isoflurane anesthesia in humans. <i>Anesthesiology</i>. 1993;79(5):943-947. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7694528\">[PubMed 7694528]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9978":"<p><b>Title</b> EPINEPHrine (Systemic) / Promethazine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Avoid epinephrine for treatment of hypotension associated with promethazine overdose. Seek alternatives to epinephrine for other indications when vasoconstrictive effects are desired.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When vasoconstrictive effects are desired in patients treated with promethazine, consider alternatives to epinephrine. Avoid epinephrine use for treatment of hypotension associated with promethazine overdose. Consider use of norepinephrine or phenylephrine instead. Use of epinephrine and promethazine in combination may still be indicated in treatment of anaphylaxis.</p> \n<p><b>Discussion</b> According to promethazine prescribing information, promethazine may diminish or reverse the pressor effects of epinephrine.<sup>1</sup> Use of epinephrine to treat hypotension associated with promethazine injection overdose, therefore, is not recommended. Use of norepinephrine or phenylephrine should be considered under such circumstances. Use of promethazine as an adjunct to epinephrine and other standard measures in anaphylaxis may still be indicated.<br><br>The exact mechanism of this interaction is unknown, and specific clinical data are unavailable. Data from dog<sup>2</sup> and human<sup>3</sup> studies demonstrate apparent opposition of epinephrine vasoconstriction and hemodynamic effects by chlorpromazine, a phenothiazine related to promethazine. Theoretically, alpha-adrenergic blocking actions of promethazine and other phenothiazines could oppose vasoconstrictive actions of epinephrine without opposing beta-stimulating effects, leading to net peripheral vasodilation and/or tachcardia.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Promethazine [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; May 2011.</p>\n<p>2. Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HF. Chlorpromazine: a study of its action on the circulation in man. <i>Lancet</i>. 1954;267(6839):614-617. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13202451\">[PubMed 13202451]</a></p>\n<p>3. Yagiela JA, Duffin SR, Hunt LM. Drug interaction and vasoconstrictors used in local anesthetic solutions. <i>Oral Surg Oral Med Oral Pathol</i>. 1985;59(6):565-571. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3892411\">[PubMed 3892411]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9979":"<p><b>Title</b> EPINEPHrine (Oral Inhalation) / Promethazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Promethazine may diminish the therapeutic effect of EPINEPHrine (Oral Inhalation). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for diminished response to inhaled epinephrine in patients treated with promethazine.</p> \n<p><b>Discussion</b> According to promethazine prescribing information, promethazine may diminish or reverse the pressor effects of epinephrine.<sup>1</sup><br><br>The exact mechanism of this interaction is unknown, and specific clinical data are unavailable. Data from dog<sup>2</sup> and human<sup>3</sup> studies demonstrate apparent opposition of epinephrine vasoconstriction and hemodynamic effects by chlorpromazine, a phenothiazine related to promethazine. Theoretically, alpha-adrenergic blocking actions of promethazine and other phenothiazines could oppose vasoconstrictive actions of epinephrine without opposing beta-stimulating effects, leading to net vasodilation.<sup>1</sup> Since local vasoconstriction is the presumed primary mechanism of action of inhaled epinephrine in relieving bronchospasm, diminished therapeutic effects could be expected in patients also receiving promethazine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Promethazine [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; May 2011.</p>\n<p>2. Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HF. Chlorpromazine: a study of its action on the circulation in man. <i>Lancet</i>. 1954;267(6839):614-617. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13202451\">[PubMed 13202451]</a></p>\n<p>3. Yagiela JA, Duffin SR, Hunt LM. Drug interaction and vasoconstrictors used in local anesthetic solutions. <i>Oral Surg Oral Med Oral Pathol</i>. 1985;59(6):565-571. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3892411\">[PubMed 3892411]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9980":"<p><b>Title</b> TraMADol / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may decrease serum concentrations of the active metabolite(s) of TraMADol. Ritonavir may increase the serum concentration of TraMADol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor tramadol response closely if used together with ritonavir. Tramadol response could be increased or decreased as a result of this combination. Tramadol dose adjustment may be needed.</p> \n<p><b>Discussion</b> The prescribing information for both ritonavir and tramadol caution that tramadol dose reduction may be required with concurrent use of these drugs,<sup>1,2,3</sup> but data regarding this purported interaction are not provided. The likely mechanisms for this interaction include inhibition of both the CYP2D6- and CYP3A4-mediated metabolism of tramadol by ritonavir, which is an inhibitor of both CYP2D6 and CYP3A4. <br><br>The AUC of tramadol was increased by 32% to 37% while the AUC of the active O-desmethyl-tramadol (M1) metabolite was decreased by 40% to 67% with concurrent use of the strong CYP2D6 inhibitor paroxetine (20 mg/day for 3 days prior to tramadol) in a clinical study of 16 healthy volunteers.<sup>4</sup> According to various experimental pain models, the analgesic potency of tramadol was also partially inhibited with concurrent paroxetine. Similarly, the tramadol AUC was an average of 115% higher and the M1 AUC was an average of 64% lower with concurrent administration of the strong CYP2D6 inhibitor terbinafine (250 mg/day) according to a study of 12 healthy volunteers.<sup>5</sup> Terbinafine administration was also associated with a decreased subjective response to tramadol.<br><br>The tramadol AUC was an average of 11% higher and the AUC of the active M1 metabolite was an average of 20% higher with concurrent administration of the strong CYP3A4 inhibitor itraconazole (200 mg/day) according to a study of 12 healthy volunteers.<sup>4</sup> According to the tramadol prescribing information, concurrent use of cimetidine, which is a moderate CYP3A4 inhibitor and moderate CYP2D6 inhibitor, was not associated with any significant change in tramadol pharmacokinetics.<sup>3</sup><br><br>Tramadol causes analgesia via a dual mechanism involving both opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake.<sup>6</sup> The active M1 metabolite of tramadol is the primary opioid agonist following tramadol administration, and this metabolite is formed via O-demethylation by CYP2D6.<sup>6</sup> Thus, inhibition of CYP2D6 activity (or presence of genetically dysfunctional CYP2D6) leads to a lower concentration of the active metabolite and less opioid-receptor-mediated analgesia. Residual (non-opioid) analgesic effects may, however, remain or be enhanced because of the resulting higher concentrations of unmetabolized tramadol. CYP3A4 is partially responsible for tramadol metabolism, mediating N-demethylation of tramadol to its M2 metabolite. Thus, inhibition of CYP3A4 activity could possibly lead to an increase in tramadol concentrations and effects or toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Norvir (ritonavir) tablet, solution [prescribing information]. North Chicago, IL: AbbVie Inc.; November 2015.</p>\n<p>2. Norvir (ritonavir) capsule [prescribing information]. North Chicago, IL: AbbVie Inc.; November 2015.</p>\n<p>3. Ultram ER (tramadol) [prescribing information]. Raritan, NJ: Ortho-McNeil, Inc.; September 2006.</p>\n<p>4. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. <i>Clin Pharmacol Ther</i>. 2005;77(4):312-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15903129\">[PubMed 15903129]</a></p>\n<p>5. Saarikoski T, Saari TI, Hagelberg NM, et al. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. <i>Eur J Clin Pharmacol</i>. 2015;71(3):321-327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25560051\">[PubMed 25560051]</a></p>\n<p>6. Grond S, Sablotzki A. Clinical pharmacology of tramadol. <i>Clin Pharmacokinet</i>. 2004;43(13):879-923. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15509185\">[PubMed 15509185]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9983":"<p><b>Title</b> AzaTHIOprine / Ribavirin (Oral Inhalation)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ribavirin (Oral Inhalation) may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using alternative agent(s) when possible. When these drugs are used in combination, monitor patients extra closely for signs/symptoms of myelosuppression.</p> \n<p><b>Discussion</b> One case series describes 8 patients with inflammatory bowel disease and hepatitis C who developed severe pancytopenia while receiving combined treatment with ribavirin (plus pegylated interferon) and azathioprine.<sup>1</sup> In all cases, the pancytopenia resolved after cessation of ribavirin, interferon, and azathioprine. Reintroduction of either ribavirin or azathioprine alone was accomplished without recurrence. Concentrations of methylated azathioprine metabolites, which have been associated with myelotoxicity, were increased 1.9- and 4.5-fold in the 2 patients who had concentrations monitored.<sup>1</sup> Similarly, another case report describes severe pancytopenia associated with concurrent use of ribavirin plus pegylated interferon alfa-2b and azathioprine, which resolved after discontinuation of all drugs and did not recur after reintroduction of ribavirin without azathioprine.<sup>2</sup> A review of 41 patients with hepatitis C who were treated with ribavirin also concluded that concurrent use of azathioprine was associated with a particularly high risk of anemia.<sup>3</sup><br><br>The mechanism of this apparent interaction is likely alteration of azathioprine metabolism by ribavirin. Specifically, it is theorized that ribavirin-mediated inhibition of inosine monophosphate dehydrogenase leads to decreased production of azathioprine 6-thioguanine nucleotides (decreased 27% and 61% with concurrent ribavirin in 2 patients per one report<sup>1</sup>) and increased methylation of azathioprine, leading to accumulation of the myelotoxic 6-methyl thioinosine monophosphate.<sup>1</sup><br><br>Although no interactions have been reported between inhaled ribavirin and azathioprine, treatment with inhaled ribavirin achieves systemic concentrations similar to that of oral ribavirin therapy, and drug interactions are expected to be similar between products.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chaparro M, Trapero-Marugan M, Moreno-Otero R, Gisbert JP. Azathioprine plus ribavirin treatment and pancytopenia. <i>Aliment Pharmacol Ther</i>. 2009;30(9):962-963. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19807727\">[PubMed 19807727]</a></p>\n<p>2. Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. <i>Aliment Pharmacol Ther</i>. 2008;28(8):984-993. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18657132\">[PubMed 18657132]</a></p>\n<p>3. Thevenot T, Mathurin P, Moussalli J, et al. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. <i>J Viral Hepat</i>. 1997;4(4):243-253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9278222\">[PubMed 9278222]</a></p>\n<p>4. Virazole (ribavirin) inhalation solution [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9984":"<p><b>Title</b> AzaTHIOprine / Ribavirin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ribavirin (Systemic) may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using alternative agent(s) when possible. When these drugs are used in combination, monitor patients closely for signs/symptoms of myelosuppression.</p> \n<p><b>Discussion</b> One case series describes 8 patients with inflammatory bowel disease and hepatitis C who developed severe pancytopenia while receiving combined treatment with ribavirin (plus pegylated interferon) and azathioprine.<sup>1</sup> In all cases, the pancytopenia resolved after cessation of ribavirin, interferon, and azathioprine. Reintroduction of either ribavirin or azathioprine alone was accomplished without recurrence. Concentrations of methylated azathioprine metabolites, which have been associated with myelotoxicity, were increased 1.9- and 4.5-fold in the 2 patients who had concentrations monitored.<sup>1</sup> Similarly, another case report describes severe pancytopenia associated with concurrent use of ribavirin plus pegylated interferon alfa-2b and azathioprine, which resolved after discontinuation of all drugs and did not recur after reintroduction of ribavirin without azathioprine.<sup>2</sup> A review of 41 patients with hepatitis C who were treated with ribavirin also concluded that concurrent use of azathioprine was associated with a particularly high risk of anemia.<sup>3</sup><br><br>The mechanism of this apparent interaction is likely alteration of azathioprine metabolism by ribavirin. Specifically, it is theorized that ribavirin-mediated inhibition of inosine monophosphate dehydrogenase leads to decreased production of azathioprine 6-thioguanine nucleotides (decreased 27% and 61% with concurrent ribavirin in 2 patients per one report<sup>1</sup>) and increased methylation of azathioprine, leading to accumulation of the myelotoxic 6-methyl thioinosine monophosphate.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chaparro M, Trapero-Marugan M, Moreno-Otero R, Gisbert JP. Azathioprine plus ribavirin treatment and pancytopenia. <i>Aliment Pharmacol Ther</i>. 2009;30(9):962-963. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19807727\">[PubMed 19807727]</a></p>\n<p>2. Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. <i>Aliment Pharmacol Ther</i>. 2008;28(8):984-993. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18657132\">[PubMed 18657132]</a></p>\n<p>3. Thevenot T, Mathurin P, Moussalli J, et al. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. <i>J Viral Hepat</i>. 1997;4(4):243-253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9278222\">[PubMed 9278222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9985":"<p><b>Title</b> Didanosine / Ribavirin (Oral Inhalation)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ribavirin (Oral Inhalation) may enhance the adverse/toxic effect of Didanosine. Ribavirin (Oral Inhalation) may increase serum concentrations of the active metabolite(s) of Didanosine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of oral ribavirin with didanosine is contraindicated. Fatal hepatic failure as well as other serious adverse events have been observed with use of these two agents together. Similar adverse events may occur with the combination of didanosine and inhaled ribavirin.</p> \n<p><b>Discussion</b> Both oral ribavirin and didanosine prescribing information warn of increased exposure to didanosine and/or its active metabolite and an increased risk for toxicity and serious adverse events (including fatal hepatoxocity, pancreatitis, lactic acidosis) associated with the concomitant use of these two agents.<sup>1,2</sup> Of 35 patients receiving both didanosine and ribavirin, 20 (57%) had one or more documented adverse events in an analysis of 89 patients receiving highly active antiretroviral therapy (HAART) and treatment for chronic hepatitis C.<sup>3</sup> Those patients receiving both ribavirin and triple nucleoside-based HAART were at particularly high risk, with an estimated hazard ratio (95% CI) of 5.3 (1.7-16.2) (p=0.003). A case report describes fatal lactic acidosis and pancreatitis in an HIV-infected patient (being treated with didanosine) while also being treated for hepatitis C with ribavirin and pegylated interferon alfa-2b.<sup>4</sup> Nucleoside reverse transcriptase inhibitors alone have been reported to cause severe, even fatal, lactic acidosis and hepatomegaly with steatosis.<sup>5,6,7</sup> <br><br>Use of didanosine with ribavirin leads to an increased exposure to dideoxyadenosine 5'-triphosphate (didanosine active metabolite) and thus an increased risk for toxicity.<sup>2</sup> The precise mechanism behind this interaction is not known. Ribavirin is not protein bound and is metabolized via reversible phosphorylation and deribosylation and amide hydrolysis. Didanosine has exhibited less than 5% protein binding in vitro and its metabolism has not been fully defined in humans. Further, when assessing the potential toxicity with use of these agents, it seems reasonable to consider the patient population being treated (eg, HCV, HIV) and their vulnerability to hepatic toxicity as well as other potential drug related toxicities.<br><br>Although no interactions have been reported between inhaled ribavirin and didanosine, treatment with inhaled ribavirin achieves systemic concentrations similar to that of oral ribavirin therapy, and drug interactions are expected to be similar between products.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rebetol (ribavirin) [prescribing information]. Kenilworth, NJ: Schering Corporation; January 2008. </p>\n<p>2. Videx EC (didanosine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; September 2008.</p>\n<p>3. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. <i>Antivir Ther</i>. 2004;9(1):133-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15040545\">[PubMed 15040545]</a></p>\n<p>4. Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. <i>AIDS Read</i>. 2003;13(7):344-348. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12889452\">[PubMed 12889452]</a></p>\n<p>5. Rosso R, Di Biagio A, Ferrazin A, Bassetti M, Ciravegna BW, Bassetti D. Fatal lactic acidosis and mimicking Guillain-Barre syndrome in an adolescent with human immunodeficiency virus infection. <i>Pediatr Infect Dis J</i>. 2003;22(7):668-670. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12886900\">[PubMed 12886900]</a></p>\n<p>6. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. <i>Clin Infect Dis</i>. 2003;36(8):1082-1085. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12684925\">[PubMed 12684925]</a></p>\n<p>7. Aramideh M, Koopmans RP, Koelman JH, Stam J. Rapidly progressing peripheral neuropathy with lactic acidosis and coproporphyria in a patient with HTLV-I associated T-cell leukaemia treated with zidovudine. <i>J Neurol</i>. 2001;248(7):621-622. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11518007\">[PubMed 11518007]</a></p>\n<p>8. Virazole (ribavirin) inhalation solution [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9986":"<p><b>Title</b> Didanosine / Ribavirin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ribavirin (Systemic) may enhance the adverse/toxic effect of Didanosine. Ribavirin (Systemic) may increase serum concentrations of the active metabolite(s) of Didanosine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ribavirin with didanosine is contraindicated. Fatal hepatic failure and other serious adverse events have been observed with concomitant use of these agents.</p> \n<p><b>Discussion</b> Both ribavirin and didanosine prescribing information warn of increased exposure to didanosine and/or its active metabolite and an increased risk for toxicity and serious adverse events (including fatal hepatoxocity, pancreatitis, lactic acidosis) associated with the concomitant use of these two agents.<sup>1,2</sup> Of 35 patients receiving both didanosine and ribavirin, 20 (57%) had one or more documented adverse events in an analysis of 89 patients receiving highly active antiretroviral therapy (HAART) and treatment for chronic hepatitis C.<sup>3</sup> Those patients receiving both ribavirin and triple nucleoside-based HAART were at particularly high risk, with an estimated hazard ratio (95% CI) of 5.3 (1.7-16.2) (p=0.003). A case report describes fatal lactic acidosis and pancreatitis in an HIV-infected patient (being treated with didanosine) while also being treated for hepatitis C with ribavirin and pegylated interferon alfa-2b.<sup>4</sup> Nucleoside reverse transcriptase inhibitors alone have been reported to cause severe, even fatal, lactic acidosis and hepatomegaly with steatosis.<sup>5,6,7</sup> <br><br>Use of didanosine with ribavirin leads to an increased exposure to dideoxyadenosine 5'-triphosphate (didanosine active metabolite) and thus an increased risk for toxicity.<sup>2</sup> The precise mechanism behind this interaction is not known. Ribavirin is not protein bound and is metabolized via reversible phosphorylation and deribosylation and amide hydrolysis. Didanosine has exhibited less than 5% protein binding in vitro and its metabolism has not been fully defined in humans. Further, when assessing the potential toxicity with use of these agents, it seems reasonable to consider the patient population being treated (eg, HCV, HIV) and their vulnerability to hepatic toxicity as well as other potential drug related toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rebetol (ribavirin) [prescribing information]. Kenilworth, NJ: Schering Corporation; January 2008. </p>\n<p>2. Videx EC (didanosine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; September 2008.</p>\n<p>3. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. <i>Antivir Ther</i>. 2004;9(1):133-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15040545\">[PubMed 15040545]</a></p>\n<p>4. Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. <i>AIDS Read</i>. 2003;13(7):344-348. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12889452\">[PubMed 12889452]</a></p>\n<p>5. Rosso R, Di Biagio A, Ferrazin A, Bassetti M, Ciravegna BW, Bassetti D. Fatal lactic acidosis and mimicking Guillain-Barre syndrome in an adolescent with human immunodeficiency virus infection. <i>Pediatr Infect Dis J</i>. 2003;22(7):668-670. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12886900\">[PubMed 12886900]</a></p>\n<p>6. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. <i>Clin Infect Dis</i>. 2003;36(8):1082-1085. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12684925\">[PubMed 12684925]</a></p>\n<p>7. Aramideh M, Koopmans RP, Koelman JH, Stam J. Rapidly progressing peripheral neuropathy with lactic acidosis and coproporphyria in a patient with HTLV-I associated T-cell leukaemia treated with zidovudine. <i>J Neurol</i>. 2001;248(7):621-622. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11518007\">[PubMed 11518007]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9987":"<p><b>Title</b> Ribavirin (Oral Inhalation) / Interferons (Alfa)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of hemolytic anemia during concomitant use of alfa interferons and inhaled ribavirin. The anemia typically occurs within the first 1 to 2 weeks of therapy. Epoetin may be needed.</p>\n<div>\n <p><b>Interferons (Alfa) Interacting Members</b> Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Peginterferon Alfa-2a, Peginterferon Alfa-2b</p>\n</div> \n<p><b>Discussion</b> An increased risk of hemolytic anemia appears to accompany the concomitant use of alpha interferon and ribavirin.<sup>1,2,3</sup> Manufacturers report an approximate 10% incidence. The cause of this increased risk is unclear. No pharmacokinetic interaction has been observed between these agents.<sup>4,5</sup><br><br>Although no interactions have been reported between inhaled ribavirin and alfa interferons, treatment with inhaled ribavirin achieves systemic concentrations similar to that of oral ribavirin therapy, and drug interactions are expected to be similar between products.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Intron A (interferon alfa-2b) [prescribing information]. Kenilworth, NJ: Schering Corporation; October 2004.</p>\n<p>2. Pegasys (peginterferon alfa-2a) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; May 2005.</p>\n<p>3. Pegintron (peginterferon alfa-2b) [prescribing information]. Kenilworth, NJ: Schering Corporation; July 2005.</p>\n<p>4. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. <i>Br J Clin Pharmacol</i>. 1998;46(6):563-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9862245\">[PubMed 9862245]</a></p>\n<p>5. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. <i>Hepatology</i>. 2000;32(3):647-653. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10960463\">[PubMed 10960463]</a></p>\n<p>6. Virazole (ribavirin) inhalation solution [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9988":"<p><b>Title</b> Ribavirin (Systemic) / Interferons (Alfa)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of hemolytic anemia during concomitant use of alfa interferons and ribavirin. The anemia typically occurs within the first 1 to 2 weeks of therapy. Epoetin may be needed.</p>\n<div>\n <p><b>Interferons (Alfa) Interacting Members</b> Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Peginterferon Alfa-2a, Peginterferon Alfa-2b</p>\n</div> \n<p><b>Discussion</b> An increased risk of hemolytic anemia appears to accompany the concomitant use of alfa interferons and ribavirin.<sup>1,2,3</sup> Manufacturers report an approximate 10% incidence. The cause of this increased risk is unclear. No pharmacokinetic interaction has been observed between these agents.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Intron A (interferon alfa-2b) [prescribing information]. Kenilworth, NJ: Schering Corporation; October 2004.</p>\n<p>2. Pegasys (peginterferon alfa-2a) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; May 2005.</p>\n<p>3. Pegintron (peginterferon alfa-2b) [prescribing information]. Kenilworth, NJ: Schering Corporation; July 2005.</p>\n<p>4. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. <i>Br J Clin Pharmacol</i>. 1998;46(6):563-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9862245\">[PubMed 9862245]</a></p>\n<p>5. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. <i>Hepatology</i>. 2000;32(3):647-653. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10960463\">[PubMed 10960463]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9989":"<p><b>Title</b> Ribavirin (Oral Inhalation) / Zidovudine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Zidovudine may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Specifically, the risk/severity of anemia may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to significantly increased risk of anemia with this combination, consider even closer monitoring for anemia than routinely recommended. Alternative therapies should also be considered when clinically possible, particularly for patients with other risk factors for ribavirin-associated anemia (eg, lower baseline hemoglobin).</p> \n<p><b>Discussion</b> Several studies of HIV-/HCV-coinfected patients who were being treated with ribavirin reported that concurrent zidovudine was associated with a greater risk of anemia and/or greater decreases in hemoglobin.<sup>1,2,3,4,5</sup> Lower baseline hemoglobin was also associated with larger magnitude declines in hemoglobin concentration in several of these studies.<sup>1,2,4</sup><br><br>Product labeling for zidovudine states that coadministration of ribavirin and zidovudine is not advised as zidovudine may exacerbate ribavirin induced anemia.<sup>6</sup><br><br>The specific mechanism for this interaction is unclear. Despite initial in vitro studies that suggested ribavirin may inhibit the intracellular phosphorylation of zidovudine,<sup>7,8</sup> in vivo studies have found no evidence of this interaction, concluding that ribavirin does not alter zidovudine phosphorylation.<sup>9,10</sup><br><br>Although no interactions have been reported between inhaled ribavirin and zidovudine, treatment with inhaled ribavirin achieves systemic concentrations similar to that of oral ribavirin therapy, and drug interactions are expected to be similar between products.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mira JA, Lopez-Cortes LF, Merino D, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. <i>Antivir Ther</i>. 2007;12(8):1225-1235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18240862\">[PubMed 18240862]</a></p>\n<p>2. Nunez M, Ocampo A, Aguirrebengoa K, et al. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. <i>J Viral Hepat</i>. 2008;15(5):363-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18179454\">[PubMed 18179454]</a></p>\n<p>3. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. <i>J Viral Hepat</i>. 2006;13(10):683-689. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16970600\">[PubMed 16970600]</a></p>\n<p>4. Fuster D, Huertas JA, Gomez G, et al. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. <i>Antivir Ther</i>. 2005;10(7):841-847. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16312180\">[PubMed 16312180]</a></p>\n<p>5. Rendon AL, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. <i>J Acquir Immune Defic Syndr</i>. 2005;39(4):401-405. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16010160\">[PubMed 16010160]</a></p>\n<p>6. Retrovir (zidovudine) [prescribing information]. Research Triangle Park, NC: Viiv Healthcare; December 2014.</p>\n<p>7. Hoggard PG, Veal GJ, Wild MJ, Barry MG, Back DJ. Drug interactions with zidovudine phosphorylation in vitro. <i>Antimicrob Agents Chemother</i>. 1995;39(6):1376-1378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7574535\">[PubMed 7574535]</a></p>\n<p>8. Sim SM, Hoggard PG, Sales SD, Phiboonbanakit D, Hart CA, Back DJ. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. <i>AIDS Res Hum Retroviruses</i>. 1998;14(18):1661-1667. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9870320\">[PubMed 9870320]</a></p>\n<p>9. Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. <i>Antimicrob Agents Chemother</i>. 2005;49(10):3997-4008. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16189072\">[PubMed 16189072]</a></p>\n<p>10. Aweeka FT, Kang M, Yu JY, et al. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s study team. <i>HIV Med</i>. 2007;8(5):288-294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17561874\">[PubMed 17561874]</a></p>\n<p>11. Virazole (ribavirin) inhalation solution [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9990":"<p><b>Title</b> Ribavirin (Systemic) / Zidovudine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Zidovudine may enhance the adverse/toxic effect of Ribavirin (Systemic). Specifically, the risk/severity of anemia may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Due to significantly increased risk of anemia with this combination, consider even closer monitoring for anemia than routinely recommended for ribavirin. Alternative therapies should also be considered when clinically possible, particularly for patients with other risk factors for ribavirin-associated anemia (eg, lower baseline hemoglobin).</p> \n<p><b>Discussion</b> Several studies of HIV/HCV-coinfected patients who were being treated with ribavirin reported that concurrent zidovudine was associated with a greater risk of anemia and/or greater decreases in hemoglobin.<sup>1,2,3,4,5</sup> Lower baseline hemoglobin was also associated with larger magnitude declines in hemoglobin concentration in several of these studies.<sup>1,2,4</sup><br><br>Product labeling for zidovudine states that coadministration of ribavirin and zidovudine is not advised because zidovudine may exacerbate ribavirin induced anemia.<sup>6</sup><br><br>The specific mechanism for this interaction is unclear. Despite initial in vitro studies that suggested ribavirin may inhibit the intracellular phosphorylation of zidovudine,<sup>7,8</sup> in vivo studies have found no evidence of this interaction, concluding that ribavirin does not alter zidovudine phosphorylation.<sup>9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mira JA, Lopez-Cortes LF, Merino D, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. <i>Antivir Ther</i>. 2007;12(8):1225-1235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18240862\">[PubMed 18240862]</a></p>\n<p>2. Nunez M, Ocampo A, Aguirrebengoa K, et al. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. <i>J Viral Hepat</i>. 2008;15(5):363-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18179454\">[PubMed 18179454]</a></p>\n<p>3. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. <i>J Viral Hepat</i>. 2006;13(10):683-689. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16970600\">[PubMed 16970600]</a></p>\n<p>4. Fuster D, Huertas JA, Gomez G, et al. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. <i>Antivir Ther</i>. 2005;10(7):841-847. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16312180\">[PubMed 16312180]</a></p>\n<p>5. Rendon AL, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. <i>J Acquir Immune Defic Syndr</i>. 2005;39(4):401-405. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16010160\">[PubMed 16010160]</a></p>\n<p>6. Retrovir (zidovudine) [prescribing information]. Research Triangle Park, NC: Viiv Healthcare; December 2014.</p>\n<p>7. Hoggard PG, Veal GJ, Wild MJ, Barry MG, Back DJ. Drug interactions with zidovudine phosphorylation in vitro. <i>Antimicrob Agents Chemother</i>. 1995;39(6):1376-1378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7574535\">[PubMed 7574535]</a></p>\n<p>8. Sim SM, Hoggard PG, Sales SD, Phiboonbanakit D, Hart CA, Back DJ. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. <i>AIDS Res Hum Retroviruses</i>. 1998;14(18):1661-1667. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9870320\">[PubMed 9870320]</a></p>\n<p>9. Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. <i>Antimicrob Agents Chemother</i>. 2005;49(10):3997-4008. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16189072\">[PubMed 16189072]</a></p>\n<p>10. Aweeka FT, Kang M, Yu JY, et al. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s study team. <i>HIV Med</i>. 2007;8(5):288-294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17561874\">[PubMed 17561874]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9991":"<p><b>Title</b> Ixazomib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of ixazomib with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The average ixazomib AUC and maximum serum concentration were 74% and 54% lower, respectively, with concurrent administration of the strong CYP3A4 inducer rifampin according to data in the ixazomib prescribing information.<sup>1,2</sup> It is recommended to avoid concurrent administration of ixazomib with strong CYP3A4 inducers.<sup>1</sup><br><br>Although the mechanism for this apparent interaction is likely increased ixazomib metabolism via induction of CYP3A4, several different enzymes may participate in ixazomib metabolism,<sup>1</sup> suggesting that induction of other enzymes may also contribute, particularly since rifampin and other strong CYP3A4 inducers also induce at least some other metabolizing enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ninlaro (ixazomib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; November 2015.</p>\n<p>2. Gupta N, Hanley MJ, Venkatakrishnan K, et al. Effects of strong CYP3A inhibition and induction on the pharmacokinetics of ixazomib, an oral proteasome inhibitor: results of drug-drug interaction studies in patients with advanced solid tumors or lymphoma and a physiologically based pharmacokinetic analysis. <i>J Clin Pharmacol</i>. 2017; Aug 11 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28800141\">[PubMed 28800141]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9992":"<p><b>Title</b> Ixazomib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Ixazomib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of ixazomib with St Johns Wort.</p> \n<p><b>Discussion</b> The average ixazomib AUC and maximum serum concentration were 74% and 54% lower, respectively, with concurrent administration of the strong CYP3A4 inducer rifampin according to data in the ixazomib prescribing information.<sup>1</sup> It is recommended to avoid concurrent administration of ixazomib with strong CYP3A4 inducers, and the ixazomib prescribing information includes St Johns Wort in this warning even though it is more of a moderate, though highly variable, CYP3A4 inducer.<sup>1</sup><br><br>Although the mechanism for this apparent interaction is likely increased ixazomib metabolism via induction of CYP3A4, several different enzymes may participate in ixazomib metabolism,<sup>1</sup> suggesting that induction of other enzymes may also contribute, particularly since rifampin and other strong CYP3A4 inducers also induce at least some other metabolizing enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ninlaro (ixazomib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9993":"<p><b>Title</b> Dronedarone / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the arrhythmogenic effect of Dronedarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of dronedarone with tricyclic antidepressants is contraindicated.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> According to the dronedarone prescribing information, concurrent use of dronedarone with drugs that prolong the QT interval and may increase the risk of Torsade de Pointes (TdP), including tricyclic antidepressants (TCAs), is contraindicated.<sup>1</sup> The precise risk for QT-prolongation and/or TdP associated with TCAs is unclear. Several case reports decribe QT-prolongation and/or TdP in patients receiving a TCA,<sup>2</sup> and the initiation of TCA treatment was associated with an average 6.9 msec QT interval increase compared to non-users in a study of 8,222 patients receiving regular ECG monitoring.<sup>3</sup> In contrast, other data suggest that with proper correction of the QT interval, TCA use is not associated with any significant difference in QT interval.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Multaq (dronedarone) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; March 2014.</p>\n<p>2. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. <i>Psychosomatics</i>. 2004;45(5):371-377. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15345781\">[PubMed 15345781]</a></p>\n<p>3. van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation. <i>J Clin Psychopharmacol</i>. 2009;29(1):9-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142100\">[PubMed 19142100]</a></p>\n<p>4. Noordam R, van den Berg ME, Niemeijer MN, et al. Assessing prolongation of the heart rate corrected QT interval in users of tricyclic antidepressants: advice to use Fridericia rather than Bazett's correction. <i>J Clin Psychopharmacol</i>. 2015;35(3):260-265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25856783\">[PubMed 25856783]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9994":"<p><b>Title</b> Dronedarone / Antipsychotic Agents (Phenothiazines)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antipsychotic Agents (Phenothiazines) may enhance the arrhythmogenic effect of Dronedarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of dronedarone with phenothiazine antipsychotics is contraindicated.</p>\n<div>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> According to the dronedarone prescribing information, concurrent use of dronedarone with drugs that prolong the QT interval and may increase the risk of Torsade de Pointes (TdP), including phenothiazine antipsychotics, is contraindicated.<sup>1</sup> Although the precise risk for QT-prolongation and/or TdP associated with TCAs is unclear, several studies have reported associations between the use of phenothiazine antipsychotics and QT-prolongation and/or TdP,<sup>2,3,4</sup> with particular associations described for thioridazine, chlorpromazine, prochlorperazine, methotrimeprazine, and fluphenazine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Multaq (dronedarone) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; March 2014.</p>\n<p>2. Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. <i>J Am Heart Assoc</i>. 2015;4(2):e001568. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25713294\">[PubMed 25713294]</a></p>\n<p>3. Xiang YT, Chiu HF, Ungvari GS, et al. QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009. <i>Hum Psychopharmacol</i>. 2015;30(2):94-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25611192\">[PubMed 25611192]</a></p>\n<p>4. Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. <i>PLoS One</i>. 2013;8(11):e81208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24278396\">[PubMed 24278396]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9995":"<p><b>Title</b> Loop Diuretics / Empagliflozin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Empagliflozin may enhance the hypotensive effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for symptoms of intravascular volume depletion (eg, postural dizziness, orthostatic hypotension, hypotension, dehydration, and syncope) if empagliflozin is combined with a loop diuretic.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> US prescribing information for empagliflozin states that the coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which may enhance the potential for volume depletion.<sup>1</sup> Similarly, the Canadian empagliflozin label states that empagliflozin may enhance the diuretic effect of loop diuretics and may increase the risk of dehydration and hypotension.<sup>2</sup><br><br>The mechanism of this interaction is excessive intravascular volume depletion due to the osmotic diuretic effect of empagliflozin combined with the volume depleting action of loop diuretics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jardiance (empagliflozin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; June 2015.</p>\n<p>2. Jardiance (empagliflozin) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}